Review Open Access
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 7, 2022; 28(1): 47-75
Published online Jan 7, 2022. doi: 10.3748/wjg.v28.i1.47
Transfusion-transmitted hepatitis E: What we know so far?
Carmen Ka Man Cheung, Man Fai Law, Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong 852, China
Sunny Hei Wong, Institute of Digestive Disease and Department of Medicine and Therapeutics, the Chinese University of Hong Kong, Hong Kong 852, China
Sunny Hei Wong, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 639798, Singapore
Alvin Wing Hin Law, West Island School, Hong Kong 852, China
ORCID number: Carmen Ka Man Cheung (0000-0001-9386-506X); Sunny Hei Wong (0000-0002-3354-9310); Alvin Wing Hin Law (0000-0001-8376-4193); Man Fai Law (0000-0003-2462-6625.).
Author contributions: Cheung CKM contributed to acquisition, analysis and interpretation of data/references; drafted and approved the manuscript; Wong SH contributed to analysis, interpretation of data/references; revised critically and approved the manuscript; Law AWH contributed to analysis of data/references and approved the manuscript; Law MF contributed to acquisition, analysis and interpretation of data/references, and drafted and approved the manuscript.
Conflict-of-interest statement: The authors declare no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Man Fai Law, MRCP, Doctor, Medicine and Therapeutics, Prince of Wales Hospital, 30-32 Ngai Shing Street, Shatin, Hong Kong 852, China. mflaw99@yahoo.com.hk
Received: April 10, 2021
Peer-review started: April 10, 2021
First decision: June 24, 2021
Revised: July 16, 2021
Accepted: December 22, 2021
Article in press: December 22, 2021
Published online: January 7, 2022

Abstract

Hepatitis E virus (HEV) is a major cause of viral hepatitis globally. There is growing concern about transfusion-transmitted HEV (TT-HEV) as an emerging global health problem. HEV can potentially result in chronic infection in immunocompromised patients, leading to a higher risk of liver cirrhosis and even death. Between 0.0013% and 0.281% of asymptomatic blood donors around the world have HEV viremia, and 0.27% to 60.5% have anti-HEV immunoglobulin G. HEV is infectious even at very low blood concentrations of the virus. Immunosuppressed patients who develop persistent hepatitis E infection should have their immunosuppressant regimen reduced; ribavirin may be considered as treatment. Pegylated interferon can be considered in those who are refractory or intolerant to ribavirin. Sofosbuvir, a nucleotide analog, showed modest antiviral activity in some clinical studies but sustained viral response was not achieved. Therefore, rescue treatment remains an unmet need. The need for HEV screening of all blood donations remains controversial. Universal screening has been adopted in some countries after consideration of risk and resource availability. Various pathogen reduction methods have also been proposed to reduce the risk of TT-HEV. Future studies are needed to define the incidence of transmission through transfusion, their clinical features, outcomes and prognosis.

Key Words: Hepatitis E virus, Acute and chronic hepatitis, Immunosuppression, Blood transfusion, Transplantation

Core Tip: Transfusion-transmitted hepatitis E virus (HEV) is an emerging global health concern. In immunocompromised patients, chronic HEV infection increases the risk of liver cirrhosis. The prevalence of viremia and anti-HEV immunoglobulin G in asymptomatic blood donors varies widely between countries but even low concentrations of HEV in blood components are infectious, and in most countries blood donations are not routinely screened for HEV. Treatment of persistent infection includes modification of the immunosuppressant regimen followed by ribavirin. The need for screening of HEV in all blood donations remains controversial. Strategies to reduce de novo HEV infection should also be emphasized.



INTRODUCTION

Hepatitis E virus (HEV) was first discovered as an epidemic of non-A, non-B hepatitis in the 1980s[1], and has since become one of the major global causes of viral hepatitis. The World Health Organization estimated that HEV caused approximately 44000 deaths in 2015, and accounted for 3.3% of global deaths related to viral hepatitis[2]. A recent meta-analysis concluded that approximately 939 million of the global population have ever experienced HEV infection, and 15 to 110 million individuals have recent or ongoing infection[3]. The infection is generally self-limiting; however, it poses a threat to some vulnerable patients resulting in a significant burden of in-patient admissions, chronic infection, organ failure, and death[4]. The mortality rate can be greater than 20% in patients with chronic liver disease, cirrhosis, or pregnancy[4,5]. With a high HEV serological prevalence among the global population, the safety of blood products has become a public health concern. Herein, we review existing evidence on transfusion-transmitted HEV (TT-HEV), and the implications for screening of blood donations.

VIROLOGY

HEV is a positive-sense, single-stranded RNA icosahedral virus belonging to the genus Orthohepevirus within the Hepeviridae family[6]. Orthohepevirus A has eight distinct genotypes, of which HEV-1, -2, -3 and -4 infect humans[7]. HEV genotype C1, belonging to the species Orthohepevirus C, circulates in rats and can cause cross-species infection and sporadic zoonotic transmission to humans[8].

HEV exists in urine or feces as non-enveloped virions encased by a capsid. It circulates in blood in a membrane-associated, quasi-enveloped form (eHEV) which is considered to be less contagious[9]. The entry mechanisms for HEV are not well characterized, but once the genomic RNA is uncoated and delivered to the cytosol, the replication cycle is initiated[10]. The viral release that initiates subsequent infection requires multivesicular bodies through endosomal sorting complexes required for transport[11].

EPIDEMIOLOGY

The prevalence rates of HEV antibody are higher in developing countries than in developed countries[12]. The highest anti-HEV immunoglobulin G (IgG) seropositivity rate has been reported in Africa with a mean of 21.76%, followed by Asia (15.80%), Europe (9.31%), North America (8.05%), South America (7.28%), and Oceania (5.99%). In addition, the reported anti-HEV immunoglobulin M (IgM) seroprevalence rate was 3.09%, 1.86%, 0.79%, 0.22% and 2.43% in Africa, Asia, Europe, North America, and South America, respectively[3].

Among the four major genotypes that can infect humans, HEV-1 and -2 are mostly found in developing countries including Asia, Africa, Latin America, and Mexico. Infection is mainly transmitted via fecally contaminated water, but occasionally also by person-to-person and vertical transmission[13]. Hepatitis E occurs as outbreaks as well as sporadic cases of acute hepatitis, with the preponderance of cases among adolescents and young adults. When stratified by age, the estimated incidence of HEV-1 and -2 infection is roughly between 0.5% and 1.0% for ages 0 to 15 years, with rates increasing to between 1.0% and 1.4% for ages 15 years to 20 years, then falling rapidly to a lower rate of 0.2% and below in individuals older than 30 years[14].

HEV-3 accounts for most of the autochthonous infection in developed countries while HEV-4 is mainly found in Asia and sporadically in Europe[15,16]. The reported seroprevalence of HEV-3 ranged from 0.6% to 52.5% in Europe, 6% in United States, 3 to 16% in United Kingdom and up to 52% in some regions of France[17]. HEV-3 and HEV-4 are zoonotic viruses which are frequently transmitted via food, close contact with animals, or transfusion of viremic blood units[18].

CLINICAL FEATURES AND EXTRAHEPATIC MANIFESTATIONS

The incubation period following exposure to HEV ranges from 2 to 6 wks. HEV infection commonly takes a clinically silent, asymptomatic course with around 5% to 30% of infected individuals developing acute hepatitis[19]. Symptoms of acute hepatitis include fever, malaise, anorexia, vomiting, followed by jaundice, tea-colored urine, and hepatomegaly[20]. It is then followed by a convalescent phase with gradual recovery within a few weeks in immunocompetent patients[21]. Acute liver failure is rare and occurs more frequently in middle-aged/elderly patients[22]. Fulminant hepatitis with fatal outcome is uncommon, but has been observed in pregnant women or in patients with pre-existing liver disease. The development of fulminant hepatitis appears to be related to host-specific factors rather than virus genotype, variants, or specific substitutions[23]. HEV superinfection may trigger liver decompensation in patients with chronic liver disease or cirrhosis, resulting in acute-on-chronic liver failure, which is associated with significant short-term mortality[24,25]. Further research is needed to clarify the clinical features, course of illness, and prognosis of patients with decompensated cirrhosis who develop HEV infection.

HEV-3 and HEV-4 can persist in immunocompromised patients resulting in chronic infection, defined as viral replication lasting for more than 3 to 6 mo[26]. It has been well described in patients after solid organ or stem cell transplant, hematology patients receiving chemotherapy, or HIV-infected patients[27-32]. The prevalence of anti-HEV IgG was about 11.6% and viral RNA was 2% in solid organ transplant recipients[33]. In solid organ transplant recipients who were positive for HEV RNA, more than 60% developed chronic hepatitis[33].

The natural history of chronic hepatitis E infection is not well understood[34]. In liver transplant recipients infected by HEV, histological analyses of liver biopsy revealed atypical morphology that is distinct from those in immunocompetent patients during early phases of infection[35]. Proliferation of, and cytokine production by, CD4+ and CD8+ T-cells were impaired in patients with persistent HEV viremia[36]. Chronic hepatitis E leads to liver fibrosis and cirrhosis. Cases of HEV-related hepatocellular carcinoma have been reported[37].

Although HEV predominantly infects hepatocytes, it may also affect other organs and present as extrahepatic manifestations. The mechanisms by which HEV can induce extrahepatic manifestations are not fully understood, but hypotheses include direct cytopathic tissue damage by extrahepatic replication, or immunological processes induced by an overwhelming host immune response[38]. Details of extrahepatic manifestations are shown in Table 1[39-44].

Table 1 Extrahepatic manifestations associated with hepatitis E virus infection.
System
Extrahepatic manifestations
NeurologicalGuillain-Barré syndrome (GBS)
Neuralgic amyotrophy
Neuropathy
Bell’s palsy
Encephalitis
Transverse myelitis
Myositis
Myasthenia gravis
Pseudotumor cerebri
Seizure
RenalDecrease glomerular filtration rate
Glomerulonephritis
Nephrotic syndrome
Mixed cryoglobulinemia
HematologicalThrombocytopenia
Hemolytic anemia
Aplastic anemia
Hemophagocytic syndrome
Monoclonal gammopathy of uncertain significance (MGUS)
OthersThyroiditis
Pancreatitis
Myocarditis
Polyarthritis
PREVALENCE IN BLOOD DONORS
Viremia

The prevalence of HEV RNA in blood donors varies around the world. (Table 2)[45-78]. Most countries have a low prevalence of HEV viremia, ranging from 0.0013% to 0.086%. A relatively higher rate of viremia was reported in Germany (0.12%) and China (0.281%)[49,70]. A meta-analysis of 10 studies from China showed a pooled prevalence of HEV RNA of 0.1%[79]. The actual prevalence might have been underestimated as some studies included in the meta-analysis conducted RNA detection only in those donors who were positive for anti-HEV IgM or antigen[79].

Table 2 Hepatitis E virus ribonucleic acid prevalence in donor, only studies include more than 1000 study subjects are included.
Ref.
Country
Initial screening method
Number of donations screened
Number positive donations
Prevalence (95%CI)
HEV genotype: n/N
Median (range) viral load, IU/mL
Outcome of recipient
Europe
Fischer et al[45], 2015AustriaRT-PCR (plasma pool of 96 samples) with 95% LOD 11.6 IU/mL5891570.012%3: 7/7(2200 to 290000)N/A
Vercouter et al[46], 2019BelgiumRT-PCR (plasma pool of 6 samples) with 95% LOD 18.6 IU/mL3813770.018%N/A(153 to 8710)N/A
Harritshøj et al[47], 2016DenmarkTMA assay on individual plasma with 95% LOD 7.9 IU/mL25637110.043% (0.02% - 0.07%)3 (in 2 samples)13 (unquantifiable to 920)(1) Look-back testing was performed in 7 recipients; all were tested negative for HEV RNA and anti-HEV IgM; (2) No recipient developed transaminitis; and (3) One patient had strongly positive anti-HEV IgG assay which may indicate recent HEV infection or secondary immune response by HEV re-exposure.
Gallian et al[48], 2014FranceRT-PCR (plasma pool of 96 samples) with 95% LOD 23 IU/mL53234220.045% (0.043%-0.047%).3c: 5/14; 3f: 8/14; 3 1/14(468 to 5155800)N/A
Westhölter et al[49], 2018GermanyRT-PCR (plasma pool of 24 samples) with 95% LOD 18.6 IU/mL18737230.123%3: 6/7(120 to 11200000)(1) Retrospective analysis of 4 viremic donors showed that they were HEV-positive in previous donations; (2) In 3 donors, testing of the previously donated blood in pools of 24 samples failed to identify viremic donations but were tpositive in unpooled samples; (3) Fourteen recipients had received HEV RNA positive blood products; (4) One immunosuppressed recipient tested positive for HEV RNA, developed acute on chronic liver failure, and died; and (5) One immunocompetent recipient developed acute self-limited episode of hepatitis E
Dreier et al[50], 2018GermanyRT-PCR with 95% LOD 4.7 IU/ml for FFP, platelet concentrates, and RBC supernatant; 95% LOD 8.9 IU/mL for RBCs.2355241820.077%3: 4/4(< 25 to 69.4)(1) Nine viremic donations were transfused to 6 different recipients; (2) Two recipients were immunocompromised (heart transplantation and leukemia); (3) Two recipients died shortly after transfusion for reasons other than HEV infection; and (4) None of the other 4 recipients developed acute HEV infection or had detectable HEV RNA / anti-HEV IgG
Corman et al[51], 2013GermanyRT-PCR (plasma pool of 96 samples mixed in metapools of 20)93955140.015%3: 14/14(3.1 to 4.8 Log10 IU/mL)N/A
Vollmer et al[52], 2012GermanyRT-PCR (plasma pool of 48 samples) with 95% LOD 4.7 IU/ml16125130.081%3: 13/13(13 to 68100)N/A
Baylis et al[53], 2012GermanyRT-PCR (plasma pool of 96 samples) with 95% LOD 250 IU/mL18,10040.022%3(3.26 to 5.35 log10 copies/mL)Donations screened positive for HEV were excluded from pharmaceutical production
O'Riordan et al[54], 2016IrelandTMA assay with 95% LOD 5.5 IU/mL2498550.020% (0.0065%-0.0467%)3: 3/3(10 to 44550)N/A
Spreafico et al[55], 2020ItalyTMA assay on individual plasma with 95% LOD 7.9 IU/mL972610.010% (0.00%-0.06%)N/AN/AN/A
Spada et al[56], 2018 ItalyRT-PCR, plasma pool and sensitivity varies according to anti-HEV IgG and IgM status100110N/AN/AN/AN/A
Hogema et al[57], 2015NetherlandsRT-PCR (plasma pool of 96 samples) with 95% LOD 38.4 IU/mL with the EasyMag extraction method and 10.3 IU/mL using Qiagen extracts59474410.069%3c: 15/17; 3f: 2/17N/AN/A
Slot et al[58], 2013NetherlandsRT-PCR (plasma pool of 48 or 480 samples) with 95% LOD 25 IU/mL40176130.032%3: 16/17(< 25 to 470000)N/A
Grabarczyk et al[59], 2018PolandTMA assay on individual plasma with 95% LOD 7.9 IU/mL12664100.079% (0.043%-0.145%)3i: 2/3; 3c: 1/3(16 to 6586 in 4 patients with positive results in qPCR)N/A
Rivero-Juarez et al[60], 2019SpainRT-PCR (plasma pool of 8 samples) with sensitivity 670 IU/mL1131340.035% (0.01%-0.09%)3: 4/4(10788 to 2000000)(1) Five patients received transfusions from HEV-infected donors; and (2) None of them showed an increase in alanine aminotransferase levels after transfusion
Sauleda et al[61], 2015 SpainTMA assay on individual plasma with 95% LOD 7.9 IU/mL999830.030% (0.01%-0.09%)3f (in 1 sample)(250 to 2755)N/A
Baylis et al[53], 2012SwedenRT-PCR (plasma pool of 96 samples) with 95% LOD 250 IU/mL95835120.013%3 (3.20 to 5.68 log10 copies/mL)Donations screened positive for HEV were excluded from pharmaceutical production
Harvala et al[62], 2019 United KingdomRT-PCR (plasma pool of 24 samples) with 95% LOD 18.6 IU/mL18387474800.026%3c: 112/149; 3e: 21/1493f: 12/149; 3a: 1/149; 2 distantly related to 3h, and 1 clustered distantly with 3a883 (1 to 3230000)N/A
Thom et al[63], 2018United KingdomRT-PCR (plasma pool of 24 samples)94302380.040%3: 10/10N/AN/A
Hewitt et al[64], 2014United KingdomRT-PCR (plasma pool of 24 samples)225000790.035%3: 79/793900 (50 to 2.37 × 106)(1) Forty-three patients who had received blood components from HEV-infected donors were followed up; (2) The overall transmission rate was 42% (18 of 43 exposed patients); (3) One recipient developed clinical hepatitis and 4 recipients developed asymptomatic transaminitis; and (4) Four heavily immunosuppressed patients had delayed (37-38 wk) seroconversion or no antibodies detected
Cleland et al[65], 2013 United KingdomNested PCR (plasma pool of 24 samples) with 95% LOD 201 IU/mL4356030.0069%3: 3/3N/AN/A
North America
Delage et al[66], 2019United StatesRT-PCR on individual samples with 95% LOD 18.6 IU/mL5072430.0059%3: 2/3; genotyping was unsuccessful in 1 patient(23 to 1420)N/A
Canada50765110.022%3 (in 1 sample) (< 10 to 3080)
Roth et al[67], 2017United StatesRT-PCR (plasma pool of 96 samples) with 95% LOD 18.6 IU/mL12802140.003%3a: 3/3(3.0 to 3.8 log IU/mL)N/A
Stramer et al[68], 2016United StatesTMA assay on individual plasma with 95% LOD 7.9 IU/mL1882920.011% (0.0018%-0.351%)N/A14 IU/mL in one sampleN/A
Xu et al[69], 2013United StatesRT-PCR (plasma pool of 7 to 8 samples) with 95% LOD 400 IU/mL and nested PCR with 95% LOD 200 IU/mL19390N/AN/AN/AN/A
Baylis et al[53], 2012United StatesRT-PCR (plasma pool of 96 samples) with 95% LOD 250 IU/mL510750N/AN/AN/AN/A
Asia
Wen et al[70], 2018 ChinaRT-PCR on individual plasma5345150.281%One 4h, another one clustered between genotype 2 and 4iN/AN/A
Tsoi et al[71], 2019 Hong KongRT-PCR with 95% LOD 7.89 IU/mL1000020.02%4 (in 1 sample)N/AN/A
Katiyar H et al[72], 2018 IndiaRT-PCR (plasma pool of 3 samples) with LOD 100 IU/mL17990N/AN/AN/AN/A
Minagi T et al[73], 2016 JapanRT-PCR (plasma pool of 50 or 500 samples) with 95% LOD 152 IU/mL620140360.0058%3: 36/36(< 1.69 to 7.22 log10 copies/mL)N/A
Intharasongkroh et al[74], 2019 ThailandRT-PCR (plasma pool of 6 samples) with 95% LOD 53.5 IU/mL30115260.086%3: 6/6N/AN/A
Others
Hoad et al[75], 2017AustraliaTMA (plasma pool of 6 samples) 7413110.0013%N/A180N/A
Shrestha et al[76], 2016 AustraliaTMA assay on individual plasma with 95% LOD 7.9 IU/mL1479910.0068% (0.0002%-0.0376%315000N/A
Hewitt et al[77], 2018New ZealandRT-PCR (plasma pool of 8 to 12 samples)50000N/AN/AN/AN/A
Maponga et al[78], 2020South AfricaTMA assay on individual plasma with 95% LOD 7.9IU/mL1000010.01%379000All donations from donors with active HEV infection were discarded

The prevalence of HEV-3 and -4 is affected by dietary habits[80]. Consumption of raw pork tartare and undercooked pork liver may represent a relevant risk factor for HEV infection in Germany[49]. Regular consumption of pork meat and shellfish were also reported in the viremic donors in China[70].

Since 70% of infections with HEV-3 and -4 are asymptomatic[81], it can be difficult to identify infected blood donors, as viremia occurs primarily during the pre-icteric phase[82]. Katiyar et al[72] described anti-HEV IgG positivity in 60.5% of the tested donors in India and yet none of them were positive for HEV RNA. In India, human HEV is caused exclusively by the HEV-1 genotype, which causes brief hepatitis and seldom results in chronic infection[83,84]. The difference in endemicity between HEV genotypes may affect the propensity to cause symptomatic disease and viral persistence, which in turn influences the likelihood of viremia among blood donors.

Other factors influencing the reported prevalence of HEV viremia are the sensitivity and plasma pool size of the various nucleic acid test screening platforms used[85]. For example, 33 of 90 donations with a viral load of 20-750 IU/mL were positive when tested individually but missed in the pooled screening in a study by Hogema et al[57]. Delage et al[66] revealed a low prevalence (n = 11/50765) and viral loads of HEV-RNA in Canadian blood donors based on individual nucleic acid amplification techniques (NAT). They postulated that if pooled NAT was used, only two positive donations with viral loads > 1000 IU/mL would have been detected. The true frequency of viremia in blood donors in studies using pooled NAT could be underestimated due to a dilution effect. Vollmer et al[86] found that screening using individual NAT yielded an approximately 50% higher detection frequency compared with NAT of a mini-pool of 96 samples; nevertheless, samples exclusively positive for individual NAT had a corresponding viral load of < 25 IU/mL. High-sensitivity individual NAT can yield false-positive results[55]. Whether the identification of low-level HEV-positive donors translates into clinical significance and whether a single individual NAT is adequate remain undefined.

Antibodies

In addition to direct detection of HEV RNA, another important indirect assessment of HEV burden is the prevalence of anti-HEV IgM and IgG in blood donors (Table 3)[45,46,54-56,58,59,61,63,65,68,69,71,72,77,87-124]. HEV IgG prevalence increases with age which likely represents the cumulative effect of HEV exposure over a lifetime, especially as IgG antibodies can persist for decades[81]. The absence of detectable antibodies in donors was related to an increased risk of transfusion transmission of HEV[64]. However, the presence of anti-HEV IgG may not always be protective as multiple HEV reinfections could occur despite pre-existing antibodies[125]. Various HEV strains in serum are capable of replication in cell culture and generate infectious particles in the culture supernatant despite the coexistence of antibodies[126]. Anti-HEV IgM could be used to detect recent infection yet it failed to identify infected donors during the window period. For example, a meta-analysis of data from 28 countries found that only 26.6% of viremic blood units had positive anti-HEV antibodies[127]. In another study by Tedder et[128] al, a significant portion of viremic individuals (n = 57/79) were seronegative at the time of donation. Anti-HEV IgM sometimes exhibits unexpectedly long persistence for up to 3 years after a self-limiting acute hepatitis E episode[129]. Only a minority of anti-HEV IgM-positive donors have detectable RNA[58,93,103,109]. All these findings suggest that detection of anti-HEV IgG or IgM alone may not provide effective screening of HEV in blood donors.

Table 3 Seroprevalence of hepatitis E in blood donors.
Ref.
Country
Number of donations screened
Assay used
Number of samples positive for HEV IgG antibodies
Anti-HEV IgG prevalence (95%CI)
Number of samples positive for HEV IgM antibodies
Anti-HEV IgM prevalence (95%CI)
Number of samples positive for HEV RNA in anti-HEV IgM positive
Viral load, IU/mL
Genotype
Europe
Fischer et al[45], 2015Austria1203 (from HEV RNA negative donors)Wantai16313.55% (11.6%-15.5%)N/AN/A0N/AN/A
Vercouter et al[46], 2019Belgium356 (from HEV RNA negative donors)Wantai318.71% (6.20%-12.10%)0N/A0N/AN/A
Miletić et al[87], 2019Croatia10363 commercial ELISA assays were used, only findings with highest prevalence are shown20920.17%464.44%0N/AN/A
Holm et al[88], 2015Denmark504In-house NIH assay5410.7% (8.2%-13.7%)N/AN/AN/AN/AN/A
Wantai10019.8% (16.4%-23.6%)
Dimeglio et al[89], 2018France300Wantai237.7% (4.9%-11.3%)20.6% (0.1%-2.4%)0N/AN/A
Juhl et al[90], 2013Germany1019RecomWell assay and Western blot696.8% (5.3%-8.3%)N/AN/AN/AN/AN/A
Dalekos et al[91], 1998Greece3016Abbott assay and Western blot80.27%0N/AN/AN/AN/A
O'Riordan et al[54], 2016Ireland1076Wantai575.3% (4.0%-6.8%)20.19%0N/AN/A
Spreafico et al[55], 2020Italy767DiaPro526.8% (5.1%-8.8%)0N/A0N/AN/A
Spada et al[56], 2018Italy10011Wantai8698.7% (8.14%-9.25%)460.4% (0.34% - 0.61%)0N/AN/A
De Sabato et al[92], 2017Italy170Bio-Chain Institute and Western blot158.82%31.76%0N/AN/A
Lucarelli et al[93], 2016Italy313Wantai15348.9% (43%-54%)20.6% (0.08%-2.3%)11003
Puttini et al[94], 2015Italy132EIAgen HEV IgG kit129.1%N/AN/AN/AN/AN/A
Hogema et al[95], 2014Netherlands513Wantai5811.31%N/AN/AN/AN/AN/A
Slot et al[58], 2013Netherlands5239Wantai140126.7% (25.6%-28.0%)490.94%4Range: < 25 to 37003
Grabarczyk et al[59], 2018Poland3079Wantai134043.52% (41.78%-45.28%)391.27% (0.93%-1.73%)N/AN/AN/A
Sauleda et al[61], 2015Spain1082Wantai21619.96% (17.60%-22.32%)131.20%0N/AN/A
Mikrogen11610.72% (8.90%-12.60%)
Mateos et al[96], 1999Spain863Abbott assay and Western blot343.9%0N/AN/AN/AN/A
Niederhauser et al[97], 2018Switzerland3609Wantai73720.4% (19.1%-21.8%)N/AN/AN/AN/AN/A
Kaufmann et al[98], 2011Switzerland550MP Biomedicals274.9%N/AN/AN/AN/AN/A
Thom et al[63], 2018United Kingdom1714Wantai1046.1% (5.0%-7.3%)N/AN/AN/AN/AN/A
Cleland et al[65], 2013United Kingdom1559Wantai734.7% (3.6%-5.8%)0N/AN/AN/AN/A
Beale et al[99], 2011United Kingdom262Wantai3111.8%41.5%0N/AN/A
North America
Zafrullah et al[100], 2018United States5040 (from HEV RNA negative donor)DSI56911.29%1462.90%0N/AN/A
MP Biomedicals53710.65%931.85%
Wantai61912.28%340.67%
Stramer et al[68], 2016United States4499MP Biomedicals3297.3% (6.6%-8.1%)260.58% (0.39%-0.85%)N/AN/AN/A
Xu et al[69], 2013United States1939Wantai36418.8% (17.0%-20.5%)80.4% (0.1%-0.7%)0N/AN/A
South America
Di Lello et al[101], 2020Argentina391DiaPro4411.3%82.0%0N/AN/A
Bangueses et al[102], 2020Uruguay400DiaPro4010%194.75%3N/A3
Asia
Nouhin et al[103], 2016Cambodia301Wantai8528.2% (23.4%-33.5%)31.0% (0.01%-1.8%)19563
Chen et al[104], 2019China4044Wantai79919.8% (18.6%-21.0%)431.1% (0.8%-1.4%)2N/A4
Wen et al[70], 2018China5345Wantai122722.96%380.71%15N/AN/A
Wang et al[105], 2017China9069Wantai268229.57%1311.44%5N/AN/A
Ma et al[106], 2015China816Wantai17221.1%40.5%0N/AN/A
Ren et al[107], 2014China10741Wantai294527.42%1091.01%0N/AN/A
Zhuang et al[108], 2014China486ELISA based on antigen protein pB166 and MPII11323.3%N/AN/AN/AN/AN/A
Tsoi et al[71], 2019Hong Kong2000Wantai31515.8% (14.2%-17.4%)160.8%0N/AN/A
Tripathy et al[109], 2019India2447Wantai43317.70% (16.23%-19.26%)50.20%2Ranged from 3.5 × 104 to 4.6 × 105 copies/mL1
Katiyar et al[72], 2018India633Wantai38360.5%N/AN/A0N/AN/A
Gajjar et al[110], 2014India460DiaProN/AN/A224.78% N/AN/AN/A
Parsa et al[111], 2016Iran700DiaPro426.0%50.71%5 (only 50 seropositive blood donors were tested)N/A1
Hesamizadeh et al[112], 2016Iran559DiaPro458.05%N/AN/AN/AN/AN/A
Naeimi et al[113], 2015Iran628HEV IgG, Pasto, Iran10516.72%N/AN/AN/AN/AN/A
Ehteram et al[114], 2013Iran530DiaPro7614.3%N/AN/AN/AN/AN/A
Taremi et al[115], 2007Iran399DiaPro317.8%N/AN/AN/AN/AN/A
Takeda et al[116], 2010Japan12600in-house ELISA4313.42%N/AN/AN/AN/AN/A
Shrestha et al[117], 2016Nepal1845Wantai77341.9% (39.7%-44.2%)553.0% (2.2%-3.8%)N/AN/AN/A
Nasrallah et al[118], 2017Qatar5854Wantai119820.46%340.58%4N/AN/A
Jupattanasin et al[119], 2019Thailand630EUROIMMUN test kit18729.7% (26.2%-33.4%)N/AN/AN/AN/AN/A
Africa
Traoré et al[120], 2016Burkina Faso1497DiaPro and Wantai58439%130.87%N/AN/AN/A
Ibrahim et al[121], 2011Egypt760N/AN/AN/A30.39%2N/AN/A
Meldal et al[122], 2013Ghana2394 commercial assays were used, findings reactive in; at least two serological assays are shown114.6%145.9%0N/AN/A
Lopes et al[123], 2017South Africa300Fortress Diagnostics7625.3%0N/AN/AN/AN/A
Ben-Ayed et al[124], 2015Tunisia426Globe; Diagnostics Srl ELISA194.46%N/AN/AN/AN/AN/A
Others
Hewitt et al[77], 2018New Zealand1013Wantai989.7% (7.9%-11.7%)N/AN/AN/AN/AN/A
MP Biomedicals828.1% (6.5%-10.0%)

Geographical variation, racial differences, and diverse study methodology and laboratory techniques all contribute to differences in HEV seroprevalence. More than one-third of donors had evidence of past HEV infection in Poland, India, Nepal and Burkina Faso[59,72,117,120]. Lucarelli et al[93] reported an unexpectedly high prevalence (48.9%) of anti-HEV IgG among 313 donors in central Italy. Eating raw dried pig liver sausage was the only independent risk factor for HEV IgG in their study, but the authors speculated that the uncontrolled expansion of the wild boar population had resulted in contamination of the soil and watercourses for people living in rural areas, and this may also have also contributed to the high prevalence of HEV[93].

Caution is needed when interpreting the HEV serology results because commercial kits for serological detection show marked variation in sensitivity and specificity. Despite the relatively high sensitivity of the IgM assay, the sensitivity of IgG detection kits is highly dependent on a patient’s immune status, being 80% to 90% in immunocompetent individuals, but falling dramatically to 15% to 45% in immunocompromised patients[130]. In a meta-analysis conducted in Europe, the pooled anti-HEV IgG seroprevalence rates determined by different commercial assays showed large variability with reported seroprevalence rates ranging from 2% to 17%[131]. Poor concordance of test results between the Wantai, Dia.Pro and MP Diagnostics HEV enzyme-linked immunosorbent assays (ELISA) were observed[132,133]. This may partly explain the broad ranges of anti-HEV IgG prevalence (5.3% to 48.9%) reported in Italy[55,56,92-94]. In contrast, most studies conducted in China used the Wantai assay and revealed a similar seroprevalence of around 20% to 30%. This assay is believed to be more sensitive than other commercial assays in detecting anti-HEV IgG[134,135].

TRANSFUSION-TRANSMITTED HEPATITIS E

HEV transmission via transfusion has been reported since 2004[136] and there has been increasing recognition of the risk of transmitting HEV by transfusion in recent years. Cases of TT-HEV are shown in Table 4[137-150]. Identical genomic sequences were identified in most infected patients and blood donors. Table 4 Likely only represents the tip of the iceberg as other probable or possible cases have been reported in the literature[151,152]. At the same time, patients with mild symptoms of hepatitis E may have gone undiagnosed. Physicians should stay vigilant for HEV infection in patients who have received a blood transfusion.

Table 4 Reported cases of transfusion transmitted hepatitis E.
Study
Number of patients
Comorbidity
Blood component received (n)
Viral load of transfused blood product IU/mL
Genotype
Treatment
Outcome
Okano et al[137], 2020 1AML on chemotherapyPltN/A3bNilSpontaneous resolution and developed HEV antibodies after cessation of chemotherapy for AML
Gallian et al[138], 201923Solid organ transplant, n = 9; allogeneic hematopoietic stem cells transplant, n = 4; hematologic malignancies, n = 5; immunosuppressant, n = 2; immunocompetent, n = 3RBC n = 7; apheresis Plt n = 3; whole blood-derived pooled Plt n = 6; FFP n = 7Ranged from 1.14 × 103 to 31 × 62.1063a, n = 1; 3c, n = 4; 3f, n = 16; 3, n = 1; 4d, n = 1Ribavirin, n = 15Acute HEV infection, n = 8; spontaneous resolution, n = 4; ribavirin treatment, n = 3; immunosuppressant reduction, n = 1; chronic HEV infection, n = 14, all immunosuppressed; resolution with ribavirin, n = 10; resolution with immunosuppressant reduction, n = 4; One solid organ transplant recipient did not clear HEV infection despite ribavirin and died of multiorgan failure
Ledesma et al[139], 20192Allogeneic BMT, n = 1; liver transplant, n = 1Plt3 × 1043eRibavirin, n = 1The patient received BMT remained HEV-infected and IgM/IgG-negative until death; the patient with liver transplant was treated successfully with a course of ribavirin
Satake et al[140]a, 201719Hematologic malignancies, n = 6; organ transplant, n = 2; systemic disease, n = 8; no major comorbidity, n = 3RBC n = 10; Plt n = 6; FFP n = 3Ranged from 1.5 × 102 to 5.3 × 106 4, n = 2N/ATwo patients with malignant lymphoma and two who had received liver transplant developed chronic hepatitis E; the two liver transplant recipients were successfully cleared of HEV by ribavirin
Lhomme et al[141], 20173Solid organ transplantOne patient received RBC; one patient received RBC and Plt; one patient received Plt and FFPRanged from 3.6 to 8.2 log IU3, n = 1; 3f, n = 2N/AN/A
Yamazaki et al[142], 20172Hematologic malignancies treated with chemotherapyN/AN/A3bN/ADid not become chronic hepatitis E
Belliere et al[143], 20171Heart transplantRBC1430 copies/mL3RibavirinDied from multi-organ failure despite treatment
Riveiro-Barciela et al[144], 20171Immunocompetent, admitted for disseminated infectionRBC750003NilSpontaneous resolution
Hoad et al[145], 20171Liver transplantFFP9473RibavirinResolved with treatment
Matsui et al[146], 20151AMI post CABG with hemorrhagic cardiac tamponadePlt106.8 copies3NilSpontaneous resolution
Huzly et al[147], 20131ImmunocompromisedApheresis Plt30888-372733fN/AN/A
Coilly et al[148], 20131Liver transplantRBC3.5 log103cRibavirinResolved with treatment
Boxall et al[149], 20061Lymphoma on chemotherapyRBCN/A3NilSpontaneous resolution
Mitsui et al[150], 20041HemodialysisRBCN/A3NilSubclinical infection without elevated ALT

Although blood components that contain larger plasma volumes, principally fresh frozen plasma and platelet components, are believed to transmit HEV more readily[64], a number of TT-HEV cases associated with red blood cell transfusion have also been described[138,140,141,143,144,148-150]. Red blood cell transfusion was a significant risk factor for HEV seropositivity in patients on hemodialysis in Croatia[153]. Twenty percent (n = 8/40) of multiply transfused thalassemia patients were anti-HEV IgG positive compared with 11.0% (n = 10/91) in blood donors[154]. In contrast, a study in Iran found anti-HEV antibodies in only 1.67% of patients with thalassemia, suggesting a low rate of TT-HEV in that country[155]. Results from these two studies in thalassemia patients were limited by the small sample size. Ankcorn et al[156] analyzed 1591 patients with hematologic malignancy and found that the more transfusions of non-HEV screened blood products the patients had received, the higher their likelihood of being IgG seroreactive was, suggesting HEV acquisition via transfusion in these patients.

A study by Hewitt et al[64] indicated that a viral concentration of between 407 and 257039 IU/mL in blood products was associated with TT-HEV, and that a high viral load in donors rendered infection more likely (P < 0.0001). However, this may not be true in immunocompromised patients. In a systematic review, Dreier et al[50] calculated the median transfused viral load in HEV-infected and non-infected immunocompromised patients. Although the transfused viral load was higher in the infected than the non-infected individuals (4.80 × 105 IU vs 1.55 × 104 IU), the between-group difference was not statistically significant (P = 0.1006)[50]. A potential reason for this finding is that a low viral concentration (150 IU/mL) of the blood component could already be infectious[140].

Most cases of TT-HEV occur in immunocompromised recipients, such as patients with hematologic malignancies, or recipients of solid organ or hematopoietic stem cell transplants. However, patients on simple immunosuppressants like corticosteroids and cyclosporine or even immunocompetent individuals are also at risk[157]. Massive transfusion increased the risk of HEV transmission in an immunocompetent trauma patient[158]. Spontaneous resolution, viral eradication by immunosuppressant reduction and/or ribavirin are possible[159] but occasionally there are cases which have progressed into chronic hepatitis, liver cirrhosis or multi-organ failure. Transfusion recipients are more vulnerable to chronic liver injury than the general population as a result of foodborne infection[140]. More than 60% (n = 56/85) of solid organ transplant recipients infected with HEV developed chronic hepatitis, with tacrolimus use as an independent predictive factor[160]. Pas et al[161] screened 1200 solid-organ transplant recipients in the Netherlands for HEV RNA and identified 12 patients with HEV infection. Nine of these 12 patients had been treated with a tacrolimus-based regimen postoperatively. In liver transplant recipients, graft hepatitis with rapid histological disease progression and requirement of re-transplantation due to liver cirrhosis has been reported[162,163]. The rapid progression of HEV infection to advanced fibrosis and cirrhosis has also been observed in individuals receiving kidney or heart transplants[33]. In 50 patients with hematologic malignancy and clinically overt hepatitis E, the mortality rate was 16% (n = 8), with liver-related death occurring in 4 patients[164]. HEV could actively suppress the cellular immune response and increase levels of immunosuppressive interleukin-10 that may perpetuate chronic infection and subsequent liver damage[165,166].

TREATMENT

The management strategy for HEV infection should be determined by the clinical presentation. Currently, there is limited information in the published literature that describes the clinical features of TT-HEV, or the optimal approach to management. Acute TT-HEV infections are usually subclinical or mild, with no severe or fulminant cases reported[140]. Therefore, most acute HEV infections should be treated conservatively, while waiting for spontaneous clearance, although a short course of ribavirin may also be considered. In 21 patients with acute HEV infection who were at high risk of liver failure, receiving immunosuppressive therapy for an autoimmune disease or undergoing chemotherapy, a short course of ribavirin for up to 3 mo was associated with rapid virological response and normalization of liver enzymes[167].

The current practice for management of chronic HEV infection is mainly based on observational data[18]; Figure 1 shows a proposed algorithm for management. In patients who are on immunosuppressants, the first-line intervention should be a dose reduction or discontinuation of the immunosuppressive drug[168,169]. In solid organ transplant recipients, reducing the dose of immunosuppressive therapies that principally target T-cells can achieve HEV clearance in nearly one third of patients[160]. Most immunosuppressive drugs such as cyclosporine and tacrolimus increase HEV replication in vitro; mycophenolate mofetil is the only immunosuppressant agent demonstrated to have an anti-viral effect[170].

Figure 1
Figure 1 Recommended algorithm for management of transfusion-transmitted hepatitis E.

If modification of the immunosuppressant regimen is not possible or is unsuccessful, pharmacological agents such as ribavirin and/or pegylated interferon-alpha (peg-IFN) can be used[171]. In a meta-analysis that included 395 patients with chronic hepatitis E, ribavirin monotherapy for a median of 3 mo achieved sustained virological response (SVR) in 76% of patients[172]. The reported dose of ribavirin in the literature ranged from 29 to 1200 mg/d, and the duration from 1 to 18 mo. Data on the optimal treatment regimen are needed[173]. HEV RNA should be assessed in the serum and in the stool before treatment discontinuation[169]. A second course of ribavirin for 6 mo can be attempted in cases of treatment failure[172]. HEV RNA concentrations decrease within the first week of initiating ribavirin therapy, and a greater reduction in viral load on day 7 is an independent predictor of SVR[174]. Ribavirin failure has been linked to the presence of certain single nucleotide variants (SNVs) and in-frame insertions in the hypervariable region of open reading frame (ORF) 1 in the HEV genome[175].

For those who are refractory to, or intolerant of, ribavirin, peg-IFN can be considered. Its efficacy has been documented in patients with hematologic disorders, patients receiving hemodialysis, and in combination with ribavirin in patients with HIV[176-178]. Close monitoring is needed if it is used in transplant recipients because of an increased risk of acute humoral and cellular rejection[179,180]. Peg-IFN was thought to be safe only in liver transplant recipients until recent case reports described its successful use in a kidney transplant recipient[181-183].

Sofosbuvir is a nucleotide analog shown to decrease replication of HEV-3 in vitro[184]. However, in clinical studies, only modest antiviral activity was observed and SVR was not achieved[185-187]. Rescue treatment for patients who are not eligible for, or not responding to, ribavirin and/or peg-IFN remains an unmet need.

HOW TO REDUCE TRANSFUSION-TRANSMITTED HEPATITIS E

The background risk of foodborne HEV transmission to both donors and recipients of blood products is not negligible. The transfusion-related risk of infection only exceeds the annual dietary risk when more than 13 individual donor components are transfused[188]. Strategies to reduce de novo infection, such as modifying eating habits and eliminating HEV from pigs and other animals that are used for food production are essential[189]. The one available vaccine (HEV 239, Hecolin, Xiamen, China) is licensed only in China, and has yet to play a fundamental role in global outbreaks or pandemic control[190]. Nonetheless, the transmissibility and disease phenotype may not be the same for a person who acquires the virus orally and a person who gets infected intravenously, as there may be some protection provided by the acidic environment of the stomach and the mucosal barrier in the gut[191]. The infectivity of the non-enveloped form is different to that of enveloped HEV[9]. Data reporting outcomes of recipients of HEV-infected blood products are sparse[47,49,50,60,64].

Policies on screening HEV in blood products differ between countries. Universal screening was adopted in the United Kingdom, Ireland, and the Netherlands. Germany and France implemented targeted screening of donated plasma intended for use in high-risk patients[192]. In Japan, the use of nucleic acid-based screening is limited to Hokkaido[193]. Blood donors are not routinely tested for HEV infection in China including Hong Kong[70,71,194]. There has been much debate on mandatory HEV screening in blood donations[195]. Key questions, such as whether or not to screen, which laboratory assay to use, which donors to screen (universal or selective screening), and which types of blood components to screen should be assessed based on risk assessment, resource availability, health economics, and political or other influences. The answers may vary considerably by geographical location[169,196]. In areas where HEV is highly endemic, most donors and/or recipients have probably been exposed to HEV previously and would have positive IgG antibodies. Therefore, the decision on serological screening should also take into consideration the prevalence of HEV infection in that particular region.

All donors should answer a questionnaire about symptoms of clinical hepatitis and potential exposure to HEV prior to blood donation. Donation should be deferred in any donors with a history of clinical hepatitis[197]. Neither alanine aminotransferase (ALT) nor anti-HEV IgM testing correlate with the presence of HEV RNA, supporting the use of NAT for screening of blood donations[60,61,105]. A simulation study by Kamp et al[198] reported that testing for HEV RNA by NAT with a pool size of 96, and a 95% limit of detection of 20 IU/mL will result in an 80% reduction in expected HEV transmissions as well as of consequent chronic infections with severe complications. The risk of transmission could be reduced by 90% in NAT using a mini-pool of 24 samples[198].

If opting for selective screening instead of universal screening, a clear definition of at-risk patients is warranted[199]. Targeted screening should be contemplated for blood components that will be supplied to transplant recipients, or patients with hematologic malignancies or chronic liver disease, as these individuals are at high risk of developing fulminant hepatitis, acute on chronic liver failure, or chronic hepatitis. However, it is not yet clear whether patients with rheumatologic diseases, those on low-intensity immunosuppression, or elderly individuals should only receive HEV-negative blood products. A multicenter retrospective study in Europe including 21 rheumatology and internal medicine patients found that patients with rheumatoid arthritis who were receiving methotrexate or biologics were at risk of chronic hepatitis E infection[200]. However, another study in France did not find worse hepatitis E severity or increased risk of chronicity in 23 patients with inflammatory arthritis treated with immunosuppressants[201].

Patients co-infected with HIV with CD4+ count < 200/mm3 are at risk for persistent HEV infection[29]. In HIV patients with low CD4+ count, anti-HEV IgG seroconversion was delayed until immune reconstitution occurred[202]. A recent meta-analysis found that the HEV RNA positivity rate was significantly higher in transplant recipients than in HIV-positive patients [1.2% (95%CI: 0.9-1.6) vs 0.39% (95%CI: 0.2-0.7); P = 0.0011], possibly due to better immune status in the HIV-positive individuals using anti-retroviral therapy[203].

HEV-1 and -2 infections can take a fulminant course in pregnancy, resulting in liver failure, membrane rupture, spontaneous abortions, and stillbirths[204]. HEV-3 infection in pregnancy appears to be less virulent without significant maternal, fetal, or neonatal complications[205-207]. During pregnancy, a reduced cellular immunity and a high level of steroid hormones, in particular estrogen, progesterone, and human chorionic gonadotropin, influence viral replication/expression and possibly explain the disease severity[208]. The immune response could be influenced by HEV genotype, translating into different outcomes[209]. Ribavirin and peg-IFN are contraindicated in pregnancy due to concerns of teratogenicity[210]. Further studies are needed to clarify the risk of transmission of HEV to pregnant women via blood transfusion; however, in view of the potentially serious disease course and absence of a safe treatment, pregnant women are a priority group for HEV-negative blood products.

Roth et al[67] evaluated the safety of plasma-derived medicinal products (PDMP) and found a very low prevalence of HEV RNA (0.002%) in plasma donors. Since viral reduction methods are used in the manufacturing processes of PDMP, these data do not support routine screening of all plasma pools intended for producing PDMP. Currently there is a lack of evidence to suggest that human serum albumin or coagulation factor concentrates are a major source of HEV infection[211,212].

The cost effectiveness of HEV screening of blood donations was analyzed in the Netherlands. Screening of whole blood donations in pools of 24 would prevent 4.52 of the 4.94 TT-HEV infections annually at a cost of approximately €310000 (Euro) per prevented chronic case. The estimated cost per incurable case prevented was 10-fold higher. Costs could potentially be reduced by 85% if only the blood products intended for use by immunocompromised patients were screened. Additional costs for selective screening may arise for logistic reasons and a possible increase in the number of blood products that expire before use. They concluded that preventing HEV transmission by screening of blood donations appears not excessively expensive compared with other blood-screening measures but the impact on disease burden may be small as only a minority of all HEV cases are transmitted by blood transfusion[213]. Another economic analysis performed in North America found a very low estimated risk of TT-HEV infection risk leading to severe liver disease. When compared with no screening, the costs were $2.68 (USD) per component for a selective screening approach, and $6.68 per component for universal screening. The respective costs per quality-adjusted life-year gained were $225546 and $561810, respectively, which exceeded the threshold for what is considered as “cost-effective”[66].

In addition to screening, various pathogen reduction methods have been proposed to reduce risk of TT-HEV. Solvent/detergent treatment could not eliminate non-enveloped HEV in plasma[214]. Non-enveloped HEV is also resistant to the Intercept method, which combines a synthetic psoralen amotosalen HCl treatment with ultraviolet A light illumination to block the replication of DNA and RNA[215]. However, substantial viral reduction has been demonstrated during the manufacturing process of plasma products using immunoaffinity chromatography, nanofiltration, cold ethanol fractionation and heat treatment[216]. Anti-HEV antibodies enhanced HEV removal by nanofiltration[217]. Furthermore, ultraviolet C light provided effective inactivation of HEV in platelet concentrates[218].

CONCLUSION

To conclude, TT-HEV is gaining attention worldwide. Although the overall prevalence of viremic blood donations is low, HEV can cause sinister consequences in immunocompromised recipients. Future studies are needed to define the incidence of transmission through transfusion, clinical features, outcomes, and prognosis. The decision on a screening policy in asymptomatic blood donors should be based on local risk assessment and health economics.

Footnotes

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Gastroenterology and Hepatology

Country/Territory of origin: China

Peer-review report’s scientific quality classification

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Anand AC, Kulkarni AV S-Editor: Chang KL L-Editor: Filipodia P-Editor: Chang KL

References
1.  Khuroo MS. Chronic liver disease after non-A, non-B hepatitis. Lancet. 1980;2:860-861.  [PubMed]  [DOI]  [Cited in This Article: ]
2.  World Health Organization  Hepatitis E Fact sheet.  [PubMed]  [DOI]  [Cited in This Article: ]
3.  Li P, Liu J, Li Y, Su J, Ma Z, Bramer WM, Cao W, de Man RA, Peppelenbosch MP, Pan Q. The global epidemiology of hepatitis E virus infection: A systematic review and meta-analysis. Liver Int. 2020;40:1516-1528.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 69]  [Cited by in F6Publishing: 92]  [Article Influence: 23.0]  [Reference Citation Analysis (0)]
4.  Wallace SJ, Swann R, Donnelly M, Kemp L, Guaci J, Murray A, Spoor J, Lin N, Miller M, Dalton HR, Hussaini SH, Gunson R, Simpson K, Stanley A, Fraser A. Mortality and morbidity of locally acquired hepatitis E in the national Scottish cohort: a multicentre retrospective study. Aliment Pharmacol Ther. 2020;51:974-986.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 14]  [Cited by in F6Publishing: 19]  [Article Influence: 4.8]  [Reference Citation Analysis (0)]
5.  Bergløv A, Hallager S, Weis N. Hepatitis E during pregnancy: Maternal and foetal case-fatality rates and adverse outcomes-A systematic review. J Viral Hepat. 2019;26:1240-1248.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 26]  [Cited by in F6Publishing: 27]  [Article Influence: 5.4]  [Reference Citation Analysis (0)]
6.  Purdy MA, Harrison TJ, Jameel S, Meng XJ, Okamoto H, Van der Poel WHM, Smith DB;  Ictv Report Consortium. ICTV Virus Taxonomy Profile: Hepeviridae. J Gen Virol. 2017;98:2645-2646.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 177]  [Cited by in F6Publishing: 180]  [Article Influence: 25.7]  [Reference Citation Analysis (0)]
7.  Primadharsini PP, Nagashima S, Okamoto H. Genetic Variability and Evolution of Hepatitis E Virus. Viruses. 2019;11.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 54]  [Cited by in F6Publishing: 65]  [Article Influence: 13.0]  [Reference Citation Analysis (0)]
8.  Sridhar S, Yip CC, Wu S, Chew NF, Leung KH, Chan JF, Zhao PS, Chan WM, Poon RW, Tsoi HW, Cai JP, Chan HS, Leung AW, Tse CW, Zee JS, Tsang OT, Cheng VC, Lau SK, Woo PC, Tsang DN, Yuen KY. Transmission of Rat Hepatitis E Virus Infection to Humans in Hong Kong: A Clinical and Epidemiological Analysis. Hepatology. 2021;73:10-22.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 78]  [Cited by in F6Publishing: 107]  [Article Influence: 35.7]  [Reference Citation Analysis (0)]
9.  Yin X, Ambardekar C, Lu Y, Feng Z. Distinct Entry Mechanisms for Nonenveloped and Quasi-Enveloped Hepatitis E Viruses. J Virol. 2016;90:4232-4242.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 132]  [Cited by in F6Publishing: 162]  [Article Influence: 20.3]  [Reference Citation Analysis (0)]
10.  Himmelsbach K, Bender D, Hildt E. Life cycle and morphogenesis of the hepatitis E virus. Emerg Microbes Infect. 2018;7:196.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 33]  [Cited by in F6Publishing: 38]  [Article Influence: 6.3]  [Reference Citation Analysis (0)]
11.  Kenney SP, Meng XJ. Hepatitis E Virus Genome Structure and Replication Strategy. Cold Spring Harb Perspect Med. 2019;9.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 65]  [Cited by in F6Publishing: 84]  [Article Influence: 16.8]  [Reference Citation Analysis (0)]
12.  Kmush B, Wierzba T, Krain L, Nelson K, Labrique AB. Epidemiology of hepatitis E in low- and middle-income countries of Asia and Africa. Semin Liver Dis. 2013;33:15-29.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 56]  [Cited by in F6Publishing: 61]  [Article Influence: 5.5]  [Reference Citation Analysis (0)]
13.  Khuroo MS, Khuroo MS, Khuroo NS. Hepatitis E: Discovery, global impact, control and cure. World J Gastroenterol. 2016;22:7030-7045.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in CrossRef: 105]  [Cited by in F6Publishing: 94]  [Article Influence: 11.8]  [Reference Citation Analysis (3)]
14.  Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology. 2012;55:988-997.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 480]  [Cited by in F6Publishing: 458]  [Article Influence: 38.2]  [Reference Citation Analysis (1)]
15.  Hakze-van der Honing RW, van Coillie E, Antonis AF, van der Poel WH. First isolation of hepatitis E virus genotype 4 in Europe through swine surveillance in the Netherlands and Belgium. PLoS One. 2011;6:e22673.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 105]  [Cited by in F6Publishing: 108]  [Article Influence: 8.3]  [Reference Citation Analysis (0)]
16.  Garbuglia AR, Scognamiglio P, Petrosillo N, Mastroianni CM, Sordillo P, Gentile D, La Scala P, Girardi E, Capobianchi MR. Hepatitis E virus genotype 4 outbreak, Italy, 2011. Emerg Infect Dis. 2013;19:110-114.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 77]  [Cited by in F6Publishing: 83]  [Article Influence: 7.5]  [Reference Citation Analysis (0)]
17.  Donnelly MC, Scobie L, Crossan CL, Dalton H, Hayes PC, Simpson KJ. Review article: hepatitis E-a concise review of virology, epidemiology, clinical presentation and therapy. Aliment Pharmacol Ther. 2017;46:126-141.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 55]  [Cited by in F6Publishing: 54]  [Article Influence: 7.7]  [Reference Citation Analysis (0)]
18.  Goel A, Aggarwal R. Hepatitis E: Epidemiology, Clinical Course, Prevention, and Treatment. Gastroenterol Clin North Am. 2020;49:315-330.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 14]  [Cited by in F6Publishing: 15]  [Article Influence: 3.8]  [Reference Citation Analysis (0)]
19.  Kamar N, Izopet J, Pavio N, Aggarwal R, Labrique A, Wedemeyer H, Dalton HR. Hepatitis E virus infection. Nat Rev Dis Primers. 2017;3:17086.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 292]  [Cited by in F6Publishing: 323]  [Article Influence: 46.1]  [Reference Citation Analysis (0)]
20.  Dalton HR, Stableforth W, Thurairajah P, Hazeldine S, Remnarace R, Usama W, Farrington L, Hamad N, Sieberhagen C, Ellis V, Mitchell J, Hussaini SH, Banks M, Ijaz S, Bendall RP. Autochthonous hepatitis E in Southwest England: natural history, complications and seasonal variation, and hepatitis E virus IgG seroprevalence in blood donors, the elderly and patients with chronic liver disease. Eur J Gastroenterol Hepatol. 2008;20:784-790.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 206]  [Cited by in F6Publishing: 202]  [Article Influence: 12.6]  [Reference Citation Analysis (0)]
21.  Lhomme S, Marion O, Abravanel F, Izopet J, Kamar N. Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections. J Clin Med. 2020;9.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 41]  [Cited by in F6Publishing: 42]  [Article Influence: 10.5]  [Reference Citation Analysis (0)]
22.  Haffar S, Shalimar, Kaur RJ, Wang Z, Prokop LJ, Murad MH, Bazerbachi F. Acute liver failure caused by hepatitis E virus genotype 3 and 4: A systematic review and pooled analysis. Liver Int. 2018;38:1965-1973.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 15]  [Cited by in F6Publishing: 15]  [Article Influence: 2.5]  [Reference Citation Analysis (0)]
23.  Smith DB, Simmonds P. Hepatitis E virus and fulminant hepatitis--a virus or host-specific pathology? Liver Int. 2015;35:1334-1340.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 30]  [Cited by in F6Publishing: 30]  [Article Influence: 3.3]  [Reference Citation Analysis (0)]
24.  Frias M, López-López P, Rivero A, Rivero-Juarez A. Role of Hepatitis E Virus Infection in Acute-on-Chronic Liver Failure. Biomed Res Int. 2018;2018:9098535.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 18]  [Cited by in F6Publishing: 19]  [Article Influence: 3.2]  [Reference Citation Analysis (0)]
25.  Radha Krishna Y, Saraswat VA, Das K, Himanshu G, Yachha SK, Aggarwal R, Choudhuri G. Clinical features and predictors of outcome in acute hepatitis A and hepatitis E virus hepatitis on cirrhosis. Liver Int. 2009;29:392-398.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 97]  [Cited by in F6Publishing: 98]  [Article Influence: 6.5]  [Reference Citation Analysis (0)]
26.  Kamar N, Rostaing L, Legrand-Abravanel F, Izopet J. How should hepatitis E virus infection be defined in organ-transplant recipients? Am J Transplant. 2013;13:1935-1936.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 99]  [Cited by in F6Publishing: 100]  [Article Influence: 9.1]  [Reference Citation Analysis (0)]
27.  Pischke S, Stiefel P, Franz B, Bremer B, Suneetha PV, Heim A, Ganzenmueller T, Schlue J, Horn-Wichmann R, Raupach R, Darnedde M, Scheibner Y, Taubert R, Haverich A, Manns MP, Wedemeyer H, Bara CL. Chronic hepatitis e in heart transplant recipients. Am J Transplant. 2012;12:3128-3133.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 124]  [Cited by in F6Publishing: 126]  [Article Influence: 10.5]  [Reference Citation Analysis (0)]
28.  Ollier L, Tieulie N, Sanderson F, Heudier P, Giordanengo V, Fuzibet JG, Nicand E. Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. Ann Intern Med. 2009;150:430-431.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 159]  [Cited by in F6Publishing: 166]  [Article Influence: 11.1]  [Reference Citation Analysis (0)]
29.  Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med. 2009;361:1025-1027.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 408]  [Cited by in F6Publishing: 412]  [Article Influence: 27.5]  [Reference Citation Analysis (0)]
30.  Sridhar S, Chan JFW, Yap DYH, Teng JLL, Huang C, Yip CCY, Hung IFN, Tang SCW, Lau SKP, Woo PCY, Yuen KY. Genotype 4 hepatitis E virus is a cause of chronic hepatitis in renal transplant recipients in Hong Kong. J Viral Hepat. 2018;25:209-213.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23]  [Cited by in F6Publishing: 21]  [Article Influence: 3.5]  [Reference Citation Analysis (0)]
31.  Wang Y, Chen G, Pan Q, Zhao J. Chronic Hepatitis E in a Renal Transplant Recipient: The First Report of Genotype 4 Hepatitis E Virus Caused Chronic Infection in Organ Recipient. Gastroenterology. 2018;154:1199-1201.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 35]  [Cited by in F6Publishing: 34]  [Article Influence: 5.7]  [Reference Citation Analysis (0)]
32.  Owada Y, Oshiro Y, Inagaki Y, Harada H, Fujiyama N, Kawagishi N, Yagisawa T, Usui J, Akutsu N, Itabashi Y, Saito K, Watarai Y, Ichimaru N, Imamura R, Kyakuno M, Ide K, Shibuya Y, Okabe Y, Ono M, Sasaki K, Shiose A, Yamagishi K, Ohnishi H, Nagashima S, Takahashi M, Yuzawa K, Okamoto H, Ohkohchi N. A Nationwide Survey of Hepatitis E Virus Infection and Chronic Hepatitis in Heart and Kidney Transplant Recipients in Japan. Transplantation. 2020;104:437-444.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 14]  [Cited by in F6Publishing: 17]  [Article Influence: 4.3]  [Reference Citation Analysis (0)]
33.  Zhou X, de Man RA, de Knegt RJ, Metselaar HJ, Peppelenbosch MP, Pan Q. Epidemiology and management of chronic hepatitis E infection in solid organ transplantation: a comprehensive literature review. Rev Med Virol. 2013;23:295-304.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 55]  [Cited by in F6Publishing: 57]  [Article Influence: 5.2]  [Reference Citation Analysis (0)]
34.  Mirazo S, Arbiza J. Hepatitis E and chronic liver damage in apparently immunocompetent individuals: Now what? Ann Hepatol. 2019;18:539-540.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2]  [Cited by in F6Publishing: 2]  [Article Influence: 0.5]  [Reference Citation Analysis (0)]
35.  Protzer U, Böhm F, Longerich T, Seebach J, Heidary Navid M, Friemel J, Marques-Maggio E, Bawohl M, Heikenwalder M, Schirmacher P, Dutkowski P, Clavien PA, Schemmer P, Schnitzler P, Gotthardt D, Müllhaupt B, Weber A. Molecular detection of hepatitis E virus (HEV) in liver biopsies after liver transplantation. Mod Pathol. 2015;28:523-532.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 32]  [Cited by in F6Publishing: 29]  [Article Influence: 3.2]  [Reference Citation Analysis (0)]
36.  Suneetha PV, Pischke S, Schlaphoff V, Grabowski J, Fytili P, Gronert A, Bremer B, Markova A, Jaroszewicz J, Bara C, Manns MP, Cornberg M, Wedemeyer H. Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatology. 2012;55:695-708.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 136]  [Cited by in F6Publishing: 131]  [Article Influence: 10.9]  [Reference Citation Analysis (0)]
37.  Borentain P, Colson P, Bolon E, Gauchez P, Coso D, Gérolami R. Hepatocellular carcinoma complicating hepatitis E virus-related cirrhosis. Hepatology. 2018;67:446-448.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 22]  [Cited by in F6Publishing: 22]  [Article Influence: 3.7]  [Reference Citation Analysis (0)]
38.  Pischke S, Hartl J, Pas SD, Lohse AW, Jacobs BC, Van der Eijk AA. Hepatitis E virus: Infection beyond the liver? J Hepatol. 2017;66:1082-1095.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 132]  [Cited by in F6Publishing: 145]  [Article Influence: 20.7]  [Reference Citation Analysis (0)]
39.  Fousekis FS, Mitselos IV, Christodoulou DK. Extrahepatic manifestations of hepatitis E virus: An overview. Clin Mol Hepatol. 2020;26:16-23.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 25]  [Cited by in F6Publishing: 31]  [Article Influence: 6.2]  [Reference Citation Analysis (0)]
40.  Kamar N, Weclawiak H, Guilbeau-Frugier C, Legrand-Abravanel F, Cointault O, Ribes D, Esposito L, Cardeau-Desangles I, Guitard J, Sallusto F, Muscari F, Peron JM, Alric L, Izopet J, Rostaing L. Hepatitis E virus and the kidney in solid-organ transplant patients. Transplantation. 2012;93:617-623.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 147]  [Cited by in F6Publishing: 148]  [Article Influence: 12.3]  [Reference Citation Analysis (0)]
41.  Noble J, Jouve T, Malvezzi P, Rostaing L. Renal complications of liver diseases. Expert Rev Gastroenterol Hepatol. 2018;12:1135-1142.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 7]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]
42.  Kamar N, Marion O, Abravanel F, Izopet J, Dalton HR. Extrahepatic manifestations of hepatitis E virus. Liver Int. 2016;36:467-472.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 81]  [Cited by in F6Publishing: 79]  [Article Influence: 9.9]  [Reference Citation Analysis (0)]
43.  Liu H, Ma Y. Hepatitis E virus-associated Guillain-Barre syndrome: Revision of the literature. Brain Behav. 2020;10:e01496.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 15]  [Article Influence: 3.8]  [Reference Citation Analysis (0)]
44.  Ripellino P, Pasi E, Melli G, Staedler C, Fraga M, Moradpour D, Sahli R, Aubert V, Martinetti G, Bihl F, Bernasconi E, Terziroli Beretta-Piccoli B, Cerny A, Dalton HR, Zehnder C, Mathis B, Zecca C, Disanto G, Kaelin-Lang A, Gobbi C. Neurologic complications of acute hepatitis E virus infection. Neurol Neuroimmunol Neuroinflamm. 2020;7.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 21]  [Cited by in F6Publishing: 30]  [Article Influence: 6.0]  [Reference Citation Analysis (0)]
45.  Fischer C, Hofmann M, Danzer M, Hofer K, Kaar J, Gabriel C. Seroprevalence and Incidence of hepatitis E in blood donors in Upper Austria. PLoS One. 2015;10:e0119576.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 72]  [Cited by in F6Publishing: 76]  [Article Influence: 8.4]  [Reference Citation Analysis (0)]
46.  Vercouter AS, Van Houtte F, Verhoye L, González Fraile I, Blanco L, Compernolle V, Meuleman P. Hepatitis E virus prevalence in Flemish blood donors. J Viral Hepat. 2019;26:1218-1223.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4]  [Cited by in F6Publishing: 4]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
47.  Harritshøj LH, Holm DK, Saekmose SG, Jensen BA, Hogema BM, Fischer TK, Midgley SE, Krog JS, Erikstrup C, Ullum H. Low transfusion transmission of hepatitis E among 25,637 single-donation, nucleic acid-tested blood donors. Transfusion. 2016;56:2225-2232.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 32]  [Cited by in F6Publishing: 33]  [Article Influence: 4.1]  [Reference Citation Analysis (0)]
48.  Gallian P, Lhomme S, Piquet Y, Sauné K, Abravanel F, Assal A, Tiberghien P, Izopet J. Hepatitis E virus infections in blood donors, France. Emerg Infect Dis. 2014;20:1914-1917.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 102]  [Cited by in F6Publishing: 105]  [Article Influence: 11.7]  [Reference Citation Analysis (0)]
49.  Westhölter D, Hiller J, Denzer U, Polywka S, Ayuk F, Rybczynski M, Horvatits T, Gundlach S, Blöcker J, Schulze Zur Wiesch J, Fischer N, Addo MM, Peine S, Göke B, Lohse AW, Lütgehetmann M, Pischke S. HEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients. J Hepatol. 2018;69:36-42.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 66]  [Cited by in F6Publishing: 66]  [Article Influence: 11.0]  [Reference Citation Analysis (0)]
50.  Dreier J, Knabbe C, Vollmer T. Transfusion-Transmitted Hepatitis E: NAT Screening of Blood Donations and Infectious Dose. Front Med (Lausanne). 2018;5:5.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 45]  [Cited by in F6Publishing: 52]  [Article Influence: 8.7]  [Reference Citation Analysis (0)]
51.  Corman VM, Drexler JF, Eckerle I, Roth WK, Drosten C, Eis-Hübinger AM. Zoonotic hepatitis E virus strains in German blood donors. Vox Sang. 2013;104:179-180.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 27]  [Cited by in F6Publishing: 28]  [Article Influence: 2.3]  [Reference Citation Analysis (1)]
52.  Vollmer T, Diekmann J, Johne R, Eberhardt M, Knabbe C, Dreier J. Novel approach for detection of hepatitis E virus infection in German blood donors. J Clin Microbiol. 2012;50:2708-2713.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 123]  [Cited by in F6Publishing: 129]  [Article Influence: 10.8]  [Reference Citation Analysis (0)]
53.  Baylis SA, Gärtner T, Nick S, Ovemyr J, Blümel J. Occurrence of hepatitis E virus RNA in plasma donations from Sweden, Germany and the United States. Vox Sang. 2012;103:89-90.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 128]  [Cited by in F6Publishing: 133]  [Article Influence: 11.1]  [Reference Citation Analysis (0)]
54.  O'Riordan J, Boland F, Williams P, Donnellan J, Hogema BM, Ijaz S, Murphy WG. Hepatitis E virus infection in the Irish blood donor population. Transfusion. 2016;56:2868-2876.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 40]  [Cited by in F6Publishing: 41]  [Article Influence: 5.1]  [Reference Citation Analysis (0)]
55.  Spreafico M, Raffaele L, Guarnori I, Foglieni B, Berzuini A, Valenti L, Gerosa A, Colli A, Prati D. Prevalence and 9-year incidence of hepatitis E virus infection among North Italian blood donors: Estimated transfusion risk. J Viral Hepat. 2020;27:858-861.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4]  [Cited by in F6Publishing: 5]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
56.  Spada E, Pupella S, Pisani G, Bruni R, Chionne P, Madonna E, Villano U, Simeoni M, Fabi S, Marano G, Marcantonio C, Pezzotti P, Ciccaglione AR, Liumbruno GM. A nationwide retrospective study on prevalence of hepatitis E virus infection in Italian blood donors. Blood Transfus. 2018;16:413-421.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 22]  [Reference Citation Analysis (0)]
57.  Hogema BM, Molier M, Sjerps M, de Waal M, van Swieten P, van de Laar T, Molenaar-de Backer M, Zaaijer HL. Incidence and duration of hepatitis E virus infection in Dutch blood donors. Transfusion. 2016;56:722-728.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 77]  [Cited by in F6Publishing: 82]  [Article Influence: 9.1]  [Reference Citation Analysis (0)]
58.  Slot E, Hogema BM, Riezebos-Brilman A, Kok TM, Molier M, Zaaijer HL. Silent hepatitis E virus infection in Dutch blood donors, 2011 to 2012. Euro Surveill. 2013;18.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 138]  [Cited by in F6Publishing: 154]  [Article Influence: 14.0]  [Reference Citation Analysis (0)]
59.  Grabarczyk P, Sulkowska E, Gdowska J, Kopacz A, Liszewski G, Kubicka-Russel D, Baylis SA, Corman VM, Noceń E, Piotrowski D, Antoniewicz-Papis J, Łętowska M. Molecular and serological infection marker screening in blood donors indicates high endemicity of hepatitis E virus in Poland. Transfusion. 2018;58:1245-1253.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 20]  [Cited by in F6Publishing: 22]  [Article Influence: 3.7]  [Reference Citation Analysis (0)]
60.  Rivero-Juarez A, Jarilla-Fernandez M, Frias M, Madrigal-Sanchez E, López-López P, Andújar-Troncoso G, Machuca I, Camacho A, Muñoz-Valbuena P, Rivero A. Hepatitis E virus in Spanish donors and the necessity for screening. J Viral Hepat. 2019;26:603-608.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 12]  [Article Influence: 2.4]  [Reference Citation Analysis (0)]
61.  Sauleda S, Ong E, Bes M, Janssen A, Cory R, Babizki M, Shin T, Lindquist A, Hoang A, Vang L, Piron M, Casamitjana N, Koppelman M, Danzig L, Linnen JM. Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription-mediated amplification assay in blood donors from Catalonia (Spain). Transfusion. 2015;55:972-979.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 97]  [Cited by in F6Publishing: 103]  [Article Influence: 10.3]  [Reference Citation Analysis (0)]
62.  Harvala H, Hewitt PE, Reynolds C, Pearson C, Haywood B, Tettmar KI, Ushiro-Lumb I, Brailsford SR, Tedder R, Ijaz S. Hepatitis E virus in blood donors in England, 2016 to 2017: from selective to universal screening. Euro Surveill. 2019;24.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 25]  [Cited by in F6Publishing: 32]  [Article Influence: 8.0]  [Reference Citation Analysis (0)]
63.  Thom K, Gilhooly P, McGowan K, Malloy K, Jarvis LM, Crossan C, Scobie L, Blatchford O, Smith-Palmer A, Donnelly MC, Davidson JS, Johannessen I, Simpson KJ, Dalton HR, Petrik J. Hepatitis E virus (HEV) in Scotland: evidence of recent increase in viral circulation in humans. Euro Surveill. 2018;23.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 31]  [Cited by in F6Publishing: 35]  [Article Influence: 7.0]  [Reference Citation Analysis (0)]
64.  Hewitt PE, Ijaz S, Brailsford SR, Brett R, Dicks S, Haywood B, Kennedy IT, Kitchen A, Patel P, Poh J, Russell K, Tettmar KI, Tossell J, Ushiro-Lumb I, Tedder RS. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet. 2014;384:1766-1773.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 399]  [Cited by in F6Publishing: 379]  [Article Influence: 37.9]  [Reference Citation Analysis (0)]
65.  Cleland A, Smith L, Crossan C, Blatchford O, Dalton HR, Scobie L, Petrik J. Hepatitis E virus in Scottish blood donors. Vox Sang. 2013;105:283-289.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 104]  [Cited by in F6Publishing: 106]  [Article Influence: 9.6]  [Reference Citation Analysis (0)]
66.  Delage G, Fearon M, Gregoire Y, Hogema BM, Custer B, Scalia V, Hawes G, Bernier F, Nguyen ML, Stramer SL. Hepatitis E Virus Infection in Blood Donors and Risk to Patients in the United States and Canada. Transfus Med Rev. 2019;33:139-145.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 13]  [Article Influence: 2.6]  [Reference Citation Analysis (1)]
67.  Roth NJ, Schäfer W, Alexander R, Elliott K, Elliott-Browne W, Knowles J, Wenzel JJ, Simon TL. Low hepatitis E virus RNA prevalence in a large-scale survey of United States source plasma donors. Transfusion. 2017;57:2958-2964.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 31]  [Cited by in F6Publishing: 32]  [Article Influence: 4.6]  [Reference Citation Analysis (0)]
68.  Stramer SL, Moritz ED, Foster GA, Ong E, Linnen JM, Hogema BM, Mak M, Chia CP, Dodd RY. Hepatitis E virus: seroprevalence and frequency of viral RNA detection among US blood donors. Transfusion. 2016;56:481-488.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 67]  [Cited by in F6Publishing: 68]  [Article Influence: 7.6]  [Reference Citation Analysis (0)]
69.  Xu C, Wang RY, Schechterly CA, Ge S, Shih JW, Xia NS, Luban NL, Alter HJ. An assessment of hepatitis E virus (HEV) in US blood donors and recipients: no detectable HEV RNA in 1939 donors tested and no evidence for HEV transmission to 362 prospectively followed recipients. Transfusion. 2013;53:2505-2511.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 86]  [Cited by in F6Publishing: 88]  [Article Influence: 8.0]  [Reference Citation Analysis (0)]
70.  Wen GP, Chen CR, Song XY, Tang ZM, Ji WF, Wang SL, Zhang K, Zhang J, Ou SH, Zheng ZZ, Xia NS. Long-term HEV carriers without antibody seroconversion among eligible immunocompetent blood donors. Emerg Microbes Infect. 2018;7:125.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 10]  [Cited by in F6Publishing: 11]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
71.  Tsoi WC, Zhu X, To AP, Holmberg J. Hepatitis E virus infection in Hong Kong blood donors. Vox Sang. 2020;115:11-17.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 6]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]
72.  Katiyar H, Goel A, Sonker A, Yadav V, Sapun S, Chaudhary R, Aggarwal R. Prevalence of hepatitis E virus viremia and antibodies among healthy blood donors in India. Indian J Gastroenterol. 2018;37:342-346.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 13]  [Article Influence: 2.2]  [Reference Citation Analysis (0)]
73.  Minagi T, Okamoto H, Ikegawa M, Ideno S, Takahashi K, Sakai K, Hagiwara K, Yunoki M, Wakisaka A. Hepatitis E virus in donor plasma collected in Japan. Vox Sang. 2016;111:242-246.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 25]  [Cited by in F6Publishing: 25]  [Article Influence: 3.1]  [Reference Citation Analysis (0)]
74.  Intharasongkroh D, Thongmee T, Sa-Nguanmoo P, Klinfueng S, Duang-In A, Wasitthankasem R, Theamboonlers A, Charoonruangrit U, Oota S, Payungporn S, Vongpunsawad S, Chirathaworn C, Poovorawan Y. Hepatitis E virus infection in Thai blood donors. Transfusion. 2019;59:1035-1043.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 13]  [Article Influence: 2.2]  [Reference Citation Analysis (0)]
75.  Hoad VC, Seed CR, Fryk JJ, Harley R, Flower RLP, Hogema BM, Kiely P, Faddy HM. Hepatitis E virus RNA in Australian blood donors: prevalence and risk assessment. Vox Sang. 2017;112:614-621.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 22]  [Cited by in F6Publishing: 25]  [Article Influence: 3.6]  [Reference Citation Analysis (0)]
76.  Shrestha AC, Flower RL, Seed CR, Keller AJ, Harley R, Chan HT, Hoad V, Warrilow D, Northill J, Holmberg JA, Faddy HM. Hepatitis E virus RNA in Australian blood donations. Transfusion. 2016;56:3086-3093.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23]  [Cited by in F6Publishing: 23]  [Article Influence: 2.9]  [Reference Citation Analysis (0)]
77.  Hewitt J, Harte D, Sutherland M, Croucher D, Fouche L, Flanagan P, Williamson D. Prevalence of hepatitis E virus antibodies and infection in New Zealand blood donors. N Z Med J. 2018;131:38-43.  [PubMed]  [DOI]  [Cited in This Article: ]
78.  Maponga TG, Lopes T, Cable R, Pistorius C, Preiser W, Andersson MI. Prevalence and risks of hepatitis E virus infection in blood donors from the Western Cape, South Africa. Vox Sang. 2020;115:695-702.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4]  [Cited by in F6Publishing: 5]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
79.  Wang M, Fu P, Yin Y, He M, Liu Y. Acute, Recent and Past HEV Infection among Voluntary Blood Donors in China: A Systematic Review and Meta-Analysis. PLoS One. 2016;11:e0161089.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 14]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
80.  Di Cola G, Fantilli AC, Pisano MB, Ré VE. Foodborne transmission of hepatitis A and hepatitis E viruses: A literature review. Int J Food Microbiol. 2021;338:108986.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 34]  [Cited by in F6Publishing: 46]  [Article Influence: 15.3]  [Reference Citation Analysis (0)]
81.  Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J, Dalton HR. Hepatitis E. Lancet. 2012;379:2477-2488.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 699]  [Cited by in F6Publishing: 688]  [Article Influence: 57.3]  [Reference Citation Analysis (0)]
82.  Pérez-Gracia MT, Suay B, Mateos-Lindemann ML. Hepatitis E: an emerging disease. Infect Genet Evol. 2014;22:40-59.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 84]  [Cited by in F6Publishing: 89]  [Article Influence: 8.9]  [Reference Citation Analysis (0)]
83.  Gupta N, Sarangi AN, Dadhich S, Dixit VK, Chetri K, Goel A, Aggarwal R. Acute hepatitis E in India appears to be caused exclusively by genotype 1 hepatitis E virus. Indian J Gastroenterol. 2018;37:44-49.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 15]  [Cited by in F6Publishing: 13]  [Article Influence: 2.2]  [Reference Citation Analysis (0)]
84.  Mevis FM, Sabeena S, Sanjay R, Robin S, Devadiga S, Prasad V, Oliver D, Ameen A, Arunkumar G. Currently circulating genotypes of hepatitis E virus in India, 2014-2018. Indian J Med Microbiol. 2019;37:563-568.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5]  [Cited by in F6Publishing: 2]  [Article Influence: 0.4]  [Reference Citation Analysis (0)]
85.  Gallian P, Couchouron A, Dupont I, Fabra C, Piquet Y, Djoudi R, Assal A, Tiberghien P. Comparison of hepatitis E virus nucleic acid test screening platforms and RNA prevalence in French blood donors. Transfusion. 2017;57:223-224.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 26]  [Cited by in F6Publishing: 25]  [Article Influence: 3.6]  [Reference Citation Analysis (0)]
86.  Vollmer T, Diekmann J, Knabbe C, Dreier J. Hepatitis E virus blood donor NAT screening: as much as possible or as much as needed? Transfusion. 2019;59:612-622.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 16]  [Cited by in F6Publishing: 21]  [Article Influence: 3.5]  [Reference Citation Analysis (0)]
87.  Miletić M, Vuk T, Hećimović A, Stojić Vidović M, Jemeršić L, Jukić I. Estimation of the hepatitis E assay-dependent seroprevalence among Croatian blood donors. Transfus Clin Biol. 2019;26:229-233.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 7]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
88.  Holm DK, Moessner BK, Engle RE, Zaaijer HL, Georgsen J, Purcell RH, Christensen PB. Declining prevalence of hepatitis E antibodies among Danish blood donors. Transfusion. 2015;55:1662-1667.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 51]  [Cited by in F6Publishing: 53]  [Article Influence: 5.9]  [Reference Citation Analysis (0)]
89.  Dimeglio C, Beau F, Broult J, Gouy P, Izopet J, Lastère S, Abravanel F. Hepatitis E prevalence in French Polynesian blood donors. PLoS One. 2018;13:e0208934.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5]  [Cited by in F6Publishing: 6]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
90.  Juhl D, Baylis SA, Blümel J, Görg S, Hennig H. Seroprevalence and incidence of hepatitis E virus infection in German blood donors. Transfusion. 2014;54:49-56.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 85]  [Cited by in F6Publishing: 91]  [Article Influence: 8.3]  [Reference Citation Analysis (0)]
91.  Dalekos GN, Zervou E, Elisaf M, Germanos N, Galanakis E, Bourantas K, Siamopoulos KC, Tsianos EV. Antibodies to hepatitis E virus among several populations in Greece: increased prevalence in an hemodialysis unit. Transfusion. 1998;38:589-595.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 43]  [Cited by in F6Publishing: 47]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
92.  De Sabato L, Di Bartolo I, Montomoli E, Trombetta C, Ruggeri FM, Ostanello F. Retrospective Study Evaluating Seroprevalence of Hepatitis E Virus in Blood Donors and in Swine Veterinarians in Italy (2004). Zoonoses Public Health. 2017;64:308-312.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11]  [Cited by in F6Publishing: 11]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
93.  Lucarelli C, Spada E, Taliani G, Chionne P, Madonna E, Marcantonio C, Pezzotti P, Bruni R, La Rosa G, Pisani G, Dell'Orso L, Ragone K, Tomei C, Ciccaglione AR. High prevalence of anti-hepatitis E virus antibodies among blood donors in central Italy, February to March 2014. Euro Surveill. 2016;21.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 47]  [Cited by in F6Publishing: 53]  [Article Influence: 6.6]  [Reference Citation Analysis (0)]
94.  Puttini C, Riccio ML, Redi D, Tordini G, Cenerini M, Romanello F, De Luca A, Carmellini M, Fossombroni V, Cusi MG, Zanelli G. Seroprevalence of hepatitis E virus (HEV) infection in blood donors and renal transplant recipients: a retrospective study from central Italy. Infez Med. 2015;23:253-256.  [PubMed]  [DOI]  [Cited in This Article: ]
95.  Hogema BM, Molier M, Slot E, Zaaijer HL. Past and present of hepatitis E in the Netherlands. Transfusion. 2014;54:3092-3096.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 67]  [Cited by in F6Publishing: 65]  [Article Influence: 6.5]  [Reference Citation Analysis (0)]
96.  Mateos ML, Camarero C, Lasa E, Teruel JL, Mir N, Baquero F. Hepatitis E virus: relevance in blood donors and risk groups. Vox Sang. 1999;76:78-80.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1]  [Cited by in F6Publishing: 13]  [Article Influence: 0.5]  [Reference Citation Analysis (0)]
97.  Niederhauser C, Widmer N, Hotz M, Tinguely C, Fontana S, Allemann G, Borri M, Infanti L, Sarraj A, Sigle J, Stalder M, Thierbach J, Waldvogel S, Wiengand T, Züger M, Gowland P. Current hepatitis E virus seroprevalence in Swiss blood donors and apparent decline from 1997 to 2016. Euro Surveill. 2018;23.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 26]  [Cited by in F6Publishing: 33]  [Article Influence: 6.6]  [Reference Citation Analysis (0)]
98.  Kaufmann A, Kenfak-Foguena A, André C, Canellini G, Bürgisser P, Moradpour D, Darling KE, Cavassini M. Hepatitis E virus seroprevalence among blood donors in southwest Switzerland. PLoS One. 2011;6:e21150.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 74]  [Cited by in F6Publishing: 76]  [Article Influence: 5.8]  [Reference Citation Analysis (0)]
99.  Beale MA, Tettmar K, Szypulska R, Tedder RS, Ijaz S. Is there evidence of recent hepatitis E virus infection in English and North Welsh blood donors? Vox Sang. 2011;100:340-342.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 78]  [Cited by in F6Publishing: 80]  [Article Influence: 5.7]  [Reference Citation Analysis (0)]
100.  Zafrullah M, Zhang X, Tran C, Nguyen M, Kamili S, Purdy MA, Stramer SL. Disparities in detection of antibodies against hepatitis E virus in US blood donor samples using commercial assays. Transfusion. 2018;58:1254-1263.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 14]  [Cited by in F6Publishing: 14]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
101.  Di Lello FA, Blejer J, Alter A, Bartoli S, Vargas F, Ruiz R, Galli C, Blanco S, Carrizo LH, Gallego S, Fernández R, Martínez AP, Flichman DM. Seroprevalence of hepatitis E virus in Argentinean blood donors. Eur J Gastroenterol Hepatol. 2020;.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4]  [Cited by in F6Publishing: 2]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]
102.  Bangueses F, Abin-Carriquiry JA, Cancela F, Curbelo J, Mirazo S. Serological and molecular prevalence of hepatitis E virus among blood donors from Uruguay. J Med Virol. 2021;93:4010-4014.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11]  [Cited by in F6Publishing: 5]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
103.  Nouhin J, Prak S, Madec Y, Barennes H, Weissel R, Hok K, Pavio N, Rouet F. Hepatitis E virus antibody prevalence, RNA frequency, and genotype among blood donors in Cambodia (Southeast Asia). Transfusion. 2016;56:2597-2601.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 10]  [Cited by in F6Publishing: 11]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
104.  Chen X, Gong P, Wagner AL, Li Y, Wang G, Lu Y. Identification of hepatitis E virus subtype 4f in blood donors in Shanghai, China. Virus Res. 2019;265:30-33.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2]  [Cited by in F6Publishing: 2]  [Article Influence: 0.4]  [Reference Citation Analysis (0)]
105.  Wang M, He M, Wu B, Ke L, Han T, Wang J, Shan H, Ness P, Guo N, Liu Y, Nelson KE. The association of elevated alanine aminotransferase levels with hepatitis E virus infections among blood donors in China. Transfusion. 2017;57:273-279.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 10]  [Cited by in F6Publishing: 10]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
106.  Ma L, Sun P, Lin F, Wang H, Rong X, Dai Y, Liu J, Qian L, Fang M, Su N, Xiao W, Ye S, Li C. Prevalence of hepatitis E virus in Chinese blood donors. J Int Med Res. 2015;43:257-262.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 10]  [Cited by in F6Publishing: 11]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]
107.  Ren F, Zhao C, Wang L, Wang Z, Gong X, Song M, Zhuang H, Huang Y, Shan H, Wang J, Liu Q, Ness P, Nelson KE, Wang Y. Hepatitis E virus seroprevalence and molecular study among blood donors in China. Transfusion. 2014;54:910-917.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 44]  [Cited by in F6Publishing: 46]  [Article Influence: 4.2]  [Reference Citation Analysis (0)]
108.  Zhuang W, Ding X, Lyu C, Xiang L, Teng H, Li J. Hepatitis E virus seroprevalence among blood donors in Jiangsu Province, East China. Int J Infect Dis. 2014;26:9-11.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 15]  [Cited by in F6Publishing: 15]  [Article Influence: 1.5]  [Reference Citation Analysis (0)]
109.  Tripathy AS, Puranik S, Sharma M, Chakraborty S, Devakate UR. Hepatitis E virus seroprevalence among blood donors in Pune, India. J Med Virol. 2019;91:813-819.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11]  [Cited by in F6Publishing: 11]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
110.  Gajjar MD, Bhatnagar NM, Sonani RV, Gupta S, Patel T. Hepatitis E seroprevalence among blood donors: A pilot study from Western India. Asian J Transfus Sci. 2014;8:29-31.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 9]  [Article Influence: 0.9]  [Reference Citation Analysis (0)]
111.  Parsa R, Adibzadeh S, Behzad Behbahani A, Farhadi A, Yaghobi R, Rafiei Dehbidi GR, Hajizamani S, Rahbar S, Nikouyan N, Okhovat MA, Naderi S, Salehi S, Alizadeh M, Ranjbaran R, Zarnegar G, Alavi P. Detection of Hepatitis E Virus Genotype 1 Among Blood Donors From Southwest of Iran. Hepat Mon. 2016;16:e34202.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 10]  [Cited by in F6Publishing: 9]  [Article Influence: 1.1]  [Reference Citation Analysis (0)]
112.  Hesamizadeh K, Sharafi H, Keyvani H, Alavian SM, Najafi-Tireh Shabankareh A, Sharifi Olyaie R, Keshvari M. Hepatitis A Virus and Hepatitis E Virus Seroprevalence Among Blood Donors in Tehran, Iran. Hepat Mon. 2016;16:e32215.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 24]  [Cited by in F6Publishing: 25]  [Article Influence: 3.1]  [Reference Citation Analysis (0)]
113.  Naeimi B, Mazloom Kalimani F, Pourfatolah AA, Azimzadeh M, Mankhian A, Akbarzadeh S, Hajiani G, Kooshesh F, Khamisipour G. Hepatitis E Virus Seroprevalence Among Blood Donors in Bushehr, South of Iran. Hepat Mon. 2015;15:e29219.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 6]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]
114.  Ehteram H, Ramezani A, Eslamifar A, Sofian M, Banifazl M, Ghassemi S, Aghakhani A, Mashayekhi P. Seroprevalence of Hepatitis E Virus infection among volunteer blood donors in central province of Iran in 2012. Iran J Microbiol. 2013;5:172-176.  [PubMed]  [DOI]  [Cited in This Article: ]
115.  Taremi M, Gachkar L, MahmoudArabi S, Kheradpezhouh M, Khoshbaten M. Prevalence of antibodies to hepatitis E virus among male blood donors in Tabriz, Islamic Republic of Iran. East Mediterr Health J. 2007;13:98-102.  [PubMed]  [DOI]  [Cited in This Article: ]
116.  Takeda H, Matsubayashi K, Sakata H, Sato S, Kato T, Hino S, Tadokoro K, Ikeda H. A nationwide survey for prevalence of hepatitis E virus antibody in qualified blood donors in Japan. Vox Sang. 2010;99:307-313.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 57]  [Cited by in F6Publishing: 61]  [Article Influence: 4.7]  [Reference Citation Analysis (0)]
117.  Shrestha AC, Flower RL, Seed CR, Rajkarnikar M, Shrestha SK, Thapa U, Hoad VC, Faddy HM. Hepatitis E virus seroepidemiology: a post-earthquake study among blood donors in Nepal. BMC Infect Dis. 2016;16:707.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 9]  [Cited by in F6Publishing: 9]  [Article Influence: 1.1]  [Reference Citation Analysis (0)]
118.  Nasrallah GK, Al Absi ES, Ghandour R, Ali NH, Taleb S, Hedaya L, Ali F, Huwaidy M, Husseini A. Seroprevalence of hepatitis E virus among blood donors in Qatar (2013-2016). Transfusion. 2017;57:1801-1807.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 36]  [Cited by in F6Publishing: 37]  [Article Influence: 5.3]  [Reference Citation Analysis (0)]
119.  Jupattanasin S, Chainuvati S, Chotiyaputta W, Chanmanee T, Supapueng O, Charoonruangrit U, Oota S, Louisirirotchanakul S. A Nationwide Survey of the Seroprevalence of Hepatitis E Virus Infections Among Blood Donors in Thailand. Viral Immunol. 2019;32:302-307.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11]  [Cited by in F6Publishing: 11]  [Article Influence: 2.2]  [Reference Citation Analysis (0)]
120.  Traoré KA, Ouoba JB, Rouamba H, Nébié YK, Dahourou H, Rossetto F, Traoré AS, Barro N, Roques P. Hepatitis E Virus Prevalence among Blood Donors, Ouagadougou, Burkina Faso. Emerg Infect Dis. 2016;22:755-757.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 9]  [Article Influence: 1.1]  [Reference Citation Analysis (0)]
121.  Ibrahim EH, Abdelwahab SF, Nady S, Hashem M, Galal G, Sobhy M, Saleh AS, Shata MT. Prevalence of anti-HEV IgM among blood donors in Egypt. Egypt J Immunol. 2011;18:47-58.  [PubMed]  [DOI]  [Cited in This Article: ]
122.  Meldal BH, Sarkodie F, Owusu-Ofori S, Allain JP. Hepatitis E virus infection in Ghanaian blood donors - the importance of immunoassay selection and confirmation. Vox Sang. 2013;104:30-36.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 24]  [Cited by in F6Publishing: 25]  [Article Influence: 2.1]  [Reference Citation Analysis (0)]
123.  Lopes T, Cable R, Pistorius C, Maponga T, Ijaz S, Preiser W, Tedder R, Andersson MI. Racial differences in seroprevalence of HAV and HEV in blood donors in the Western Cape, South Africa: a clue to the predominant HEV genotype? Epidemiol Infect. 2017;145:1910-1912.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 7]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
124.  Ben-Ayed Y, Hannachi H, Ben-Alaya-Bouafif N, Gouider E, Triki H, Bahri O. Hepatitis E virus seroprevalence among hemodialysis and hemophiliac patients in Tunisia (North Africa). J Med Virol. 2015;87:441-445.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 13]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
125.  Schemmerer M, Rauh C, Jilg W, Wenzel JJ. Time course of hepatitis E-specific antibodies in adults. J Viral Hepat. 2017;24:75-79.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 21]  [Cited by in F6Publishing: 18]  [Article Influence: 2.6]  [Reference Citation Analysis (0)]
126.  Takahashi M, Tanaka T, Takahashi H, Hoshino Y, Nagashima S, Jirintai, Mizuo H, Yazaki Y, Takagi T, Azuma M, Kusano E, Isoda N, Sugano K, Okamoto H. Hepatitis E Virus (HEV) strains in serum samples can replicate efficiently in cultured cells despite the coexistence of HEV antibodies: characterization of HEV virions in blood circulation. J Clin Microbiol. 2010;48:1112-1125.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 191]  [Cited by in F6Publishing: 201]  [Article Influence: 14.4]  [Reference Citation Analysis (0)]
127.  Goel A, Vijay HJ, Katiyar H, Aggarwal R. Prevalence of hepatitis E viraemia among blood donors: a systematic review. Vox Sang. 2020;115:120-132.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 16]  [Cited by in F6Publishing: 9]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
128.  Tedder RS, Tettmar KI, Brailsford SR, Said B, Ushiro-Lumb I, Kitchen A, Morgan D, Lattimore S, Tossell J, Ijaz S, Hewitt PE. Virology, serology, and demography of hepatitis E viremic blood donors in South East England. Transfusion. 2016;56:1529-1536.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 33]  [Cited by in F6Publishing: 33]  [Article Influence: 4.1]  [Reference Citation Analysis (0)]
129.  Riveiro-Barciela M, Rando-Segura A, Barreira-Díaz A, Bes M, P Ruzo S, Piron M, Quer J, Sauleda S, Rodríguez-Frías F, Esteban R, Buti M. Unexpected long-lasting anti-HEV IgM positivity: Is HEV antigen a better serological marker for hepatitis E infection diagnosis? J Viral Hepat. 2020;27:747-753.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 18]  [Cited by in F6Publishing: 18]  [Article Influence: 4.5]  [Reference Citation Analysis (0)]
130.  Kar P, Karna R. A Review of the Diagnosis and Management of Hepatitis E. Infect Dis. 2020;1-11.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11]  [Cited by in F6Publishing: 11]  [Article Influence: 2.8]  [Reference Citation Analysis (0)]
131.  Hartl J, Otto B, Madden RG, Webb G, Woolson KL, Kriston L, Vettorazzi E, Lohse AW, Dalton HR, Pischke S. Hepatitis E Seroprevalence in Europe: A Meta-Analysis. Viruses. 2016;8.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 145]  [Cited by in F6Publishing: 160]  [Article Influence: 20.0]  [Reference Citation Analysis (0)]
132.  Shrestha AC, Flower RL, Seed CR, Stramer SL, Faddy HM. A Comparative Study of Assay Performance of Commercial Hepatitis E Virus Enzyme-Linked Immunosorbent Assay Kits in Australian Blood Donor Samples. J Blood Transfus. 2016;2016:9647675.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 18]  [Cited by in F6Publishing: 18]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
133.  Galli C, Fomiatti L, Tagliacarne C, Velati C, Zanetti AR, Castaldi S, Romanò L. Seroprevalence of hepatitis E virus among blood donors in northern Italy (Sondrio, Lombardy) determined by three different assays. Blood Transfus. 2017;15:502-505.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 8]  [Reference Citation Analysis (0)]
134.  Park HK, Jeong SH, Kim JW, Woo BH, Lee DH, Kim HY, Ahn S. Seroprevalence of anti-hepatitis E virus (HEV) in a Korean population: comparison of two commercial anti-HEV assays. BMC Infect Dis. 2012;12:142.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 42]  [Cited by in F6Publishing: 45]  [Article Influence: 3.8]  [Reference Citation Analysis (0)]
135.  Bendall R, Ellis V, Ijaz S, Ali R, Dalton H. A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. J Med Virol. 2010;82:799-805.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 243]  [Cited by in F6Publishing: 253]  [Article Influence: 18.1]  [Reference Citation Analysis (0)]
136.  Matsubayashi K, Nagaoka Y, Sakata H, Sato S, Fukai K, Kato T, Takahashi K, Mishiro S, Imai M, Takeda N, Ikeda H. Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan. Transfusion. 2004;44:934-940.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 221]  [Cited by in F6Publishing: 217]  [Article Influence: 10.9]  [Reference Citation Analysis (0)]
137.  Okano H, Nakano T, Ito R, Tanaka A, Hoshi Y, Matsubayashi K, Asakawa H, Nose K, Tsuruga S, Tochio T, Kumazawa H, Isono Y, Tanaka H, Matsusaki S, Sase T, Saito T, Mukai K, Nishimura A, Kawakami K, Nagashima S, Takahashi M, Okamoto H. The spontaneous clearance of hepatitis E virus (HEV) and emergence of HEV antibodies in a transfusion-transmitted chronic hepatitis E case after completion of chemotherapy for acute myeloid leukemia. Clin J Gastroenterol. 2020;13:252-259.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5]  [Cited by in F6Publishing: 6]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]
138.  Gallian P, Pouchol E, Djoudi R, Lhomme S, Mouna L, Gross S, Bierling P, Assal A, Kamar N, Mallet V, Roque-Afonso AM, Izopet J, Tiberghien P. Transfusion-Transmitted Hepatitis E Virus Infection in France. Transfus Med Rev. 2019;33:146-153.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 27]  [Cited by in F6Publishing: 30]  [Article Influence: 6.0]  [Reference Citation Analysis (0)]
139.  Ledesma J, Williams D, Stanford FA, Hewitt PE, Zuckerman M, Bansal S, Dhawan A, Mbisa JL, Tedder R, Ijaz S. Resolution by deep sequencing of a dual hepatitis E virus infection transmitted via blood components. J Gen Virol. 2019;100:1491-1500.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3]  [Cited by in F6Publishing: 3]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
140.  Satake M, Matsubayashi K, Hoshi Y, Taira R, Furui Y, Kokudo N, Akamatsu N, Yoshizumi T, Ohkohchi N, Okamoto H, Miyoshi M, Tamura A, Fuse K, Tadokoro K. Unique clinical courses of transfusion-transmitted hepatitis E in patients with immunosuppression. Transfusion. 2017;57:280-288.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 49]  [Cited by in F6Publishing: 52]  [Article Influence: 7.4]  [Reference Citation Analysis (0)]
141.  Lhomme S, Bardiaux L, Abravanel F, Gallian P, Kamar N, Izopet J. Hepatitis E Virus Infection in Solid Organ Transplant Recipients, France. Emerg Infect Dis. 2017;23:353-356.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 21]  [Cited by in F6Publishing: 21]  [Article Influence: 3.5]  [Reference Citation Analysis (0)]
142.  Yamazaki Y, Naganuma A, Arai Y, Takeuchi S, Kobayashi T, Takakusagi S, Hatanaka T, Hoshino T, Namikawa M, Hashizume H, Takizawa D, Ohyama T, Suzuki H, Horiguchi N, Takagi H, Sato K, Kakizaki S, Kusano M, Nagashima S, Takahashi M, Okamoto H, Yamada M. Clinical and virological features of acute hepatitis E in Gunma prefecture, Japan between 2004 and 2015. Hepatol Res. 2017;47:435-445.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 12]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
143.  Belliere J, Abravanel F, Nogier MB, Martinez S, Cintas P, Lhomme S, Lavayssière L, Cointault O, Faguer S, Izopet J, Kamar N. Transfusion-acquired hepatitis E infection misdiagnosed as severe critical illness polyneuromyopathy in a heart transplant patient. Transpl Infect Dis. 2017;19.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11]  [Cited by in F6Publishing: 11]  [Article Influence: 1.6]  [Reference Citation Analysis (0)]
144.  Riveiro-Barciela M, Sauleda S, Quer J, Salvador F, Gregori J, Pirón M, Rodríguez-Frías F, Buti M. Red blood cell transfusion-transmitted acute hepatitis E in an immunocompetent subject in Europe: a case report. Transfusion. 2017;57:244-247.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 32]  [Cited by in F6Publishing: 29]  [Article Influence: 4.1]  [Reference Citation Analysis (0)]
145.  Hoad VC, Gibbs T, Ravikumara M, Nash M, Levy A, Tracy SL, Mews C, Perkowska-Guse Z, Faddy HM, Bowden S. First confirmed case of transfusion-transmitted hepatitis E in Australia. Med J Aust. 2017;206:289-290.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 14]  [Cited by in F6Publishing: 14]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
146.  Matsui T, Kang JH, Matsubayashi K, Yamazaki H, Nagai K, Sakata H, Tsuji K, Maguchi H. Rare case of transfusion-transmitted hepatitis E from the blood of a donor infected with the hepatitis E virus genotype 3 indigenous to Japan: Viral dynamics from onset to recovery. Hepatol Res. 2015;45:698-704.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 25]  [Cited by in F6Publishing: 24]  [Article Influence: 2.7]  [Reference Citation Analysis (0)]
147.  Huzly D, Umhau M, Bettinger D, Cathomen T, Emmerich F, Hasselblatt P, Hengel H, Herzog R, Kappert O, Maassen S, Schorb E, Schulz-Huotari C, Thimme R, Unmüssig R, Wenzel JJ, Panning M. Transfusion-transmitted hepatitis E in Germany, 2013. Euro Surveill. 2014;19.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 65]  [Cited by in F6Publishing: 69]  [Article Influence: 6.9]  [Reference Citation Analysis (0)]
148.  Coilly A, Haïm-Boukobza S, Roche B, Antonini TM, Pause A, Mokhtari C, Becq A, Farahmand H, Hauser L, Duclos-Vallée JC, Samuel D, Adam R, Roque-Afonso AM. Posttransplantation hepatitis E: transfusion-transmitted hepatitis rising from the ashes. Transplantation. 2013;96:e4-e6.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 38]  [Cited by in F6Publishing: 38]  [Article Influence: 3.5]  [Reference Citation Analysis (0)]
149.  Boxall E, Herborn A, Kochethu G, Pratt G, Adams D, Ijaz S, Teo CG. Transfusion-transmitted hepatitis E in a 'nonhyperendemic' country. Transfus Med. 2006;16:79-83.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 231]  [Cited by in F6Publishing: 236]  [Article Influence: 13.1]  [Reference Citation Analysis (0)]
150.  Mitsui T, Tsukamoto Y, Yamazaki C, Masuko K, Tsuda F, Takahashi M, Nishizawa T, Okamoto H. Prevalence of hepatitis E virus infection among hemodialysis patients in Japan: evidence for infection with a genotype 3 HEV by blood transfusion. J Med Virol. 2004;74:563-572.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 120]  [Cited by in F6Publishing: 132]  [Article Influence: 6.6]  [Reference Citation Analysis (0)]
151.  Ticehurst JR, Pisanic N, Forman MS, Ordak C, Heaney CD, Ong E, Linnen JM, Ness PM, Guo N, Shan H, Nelson KE. Probable transmission of hepatitis E virus (HEV) via transfusion in the United States. Transfusion. 2019;59:1024-1034.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 18]  [Cited by in F6Publishing: 13]  [Article Influence: 2.6]  [Reference Citation Analysis (0)]
152.  Andonov A, Rock G, Lin L, Borlang J, Hooper J, Grudeski E, Wu J; Members of the Canadian Apheresis Group (CAG). Serological and molecular evidence of a plausible transmission of hepatitis E virus through pooled plasma. Vox Sang. 2014;107:213-219.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 34]  [Cited by in F6Publishing: 35]  [Article Influence: 3.5]  [Reference Citation Analysis (0)]
153.  Mrzljak A, Dinjar-Kujundzic P, Knotek M, Kudumija B, Ilic M, Gulin M, Zibar L, Hrstic I, Jurekovic Z, Kolaric B, Jemersic L, Prpic J, Tomljenovic M, Vilibic-Cavlek T. Seroepidemiology of hepatitis E in patients on haemodialysis in Croatia. Int Urol Nephrol. 2020;52:371-378.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Cited by in F6Publishing: 7]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
154.  Slavov SN, Maçonetto JDM, Martinez EZ, Silva-Pinto AC, Covas DT, Eis-Hübinger AM, Kashima S. Prevalence of hepatitis E virus infection in multiple transfused Brazilian patients with thalassemia and sickle cell disease. J Med Virol. 2019;91:1693-1697.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 6]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]
155.  Dalvand N, Dalvand A, Sharifi Z, Hosseini SM. Prevalence of hepatitis E virus in thalassemia patients with hepatitis C in Tehran, Iran. Iran J Microbiol. 2019;11:535-540.  [PubMed]  [DOI]  [Cited in This Article: ]
156.  Ankcorn MJ, Fox TA, Ijaz S, Nicholas C, Houston E, Longair I, Suri D, Mattes FM, Walker JL, Tedder RS, Sekhar M. Characterising the risk of Hepatitis E virus infection in haematological malignancies: a UK prospective prevalence study. Br J Haematol. 2019;186:191-195.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 7]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
157.  Haïm-Boukobza S, Ferey MP, Vétillard AL, Jeblaoui A, Pélissier E, Pelletier G, Teillet L, Roque-Afonso AM. Transfusion-transmitted hepatitis E in a misleading context of autoimmunity and drug-induced toxicity. J Hepatol. 2012;57:1374-1378.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 60]  [Cited by in F6Publishing: 62]  [Article Influence: 5.2]  [Reference Citation Analysis (0)]
158.  Loyrion E, Trouve-Buisson T, Pouzol P, Larrat S, Decaens T, Payen JF. Hepatitis E Virus Infection after Platelet Transfusion in an Immunocompetent Trauma Patient. Emerg Infect Dis. 2017;23:146-147.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 17]  [Cited by in F6Publishing: 17]  [Article Influence: 2.8]  [Reference Citation Analysis (0)]
159.  Peters van Ton AM, Gevers TJ, Drenth JP. Antiviral therapy in chronic hepatitis E: a systematic review. J Viral Hepat. 2015;22:965-973.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 40]  [Cited by in F6Publishing: 37]  [Article Influence: 4.1]  [Reference Citation Analysis (0)]
160.  Kamar N, Garrouste C, Haagsma EB, Garrigue V, Pischke S, Chauvet C, Dumortier J, Cannesson A, Cassuto-Viguier E, Thervet E, Conti F, Lebray P, Dalton HR, Santella R, Kanaan N, Essig M, Mousson C, Radenne S, Roque-Afonso AM, Izopet J, Rostaing L. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology. 2011;140:1481-1489.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 475]  [Cited by in F6Publishing: 449]  [Article Influence: 34.5]  [Reference Citation Analysis (0)]
161.  Pas SD, de Man RA, Mulders C, Balk AH, van Hal PT, Weimar W, Koopmans MP, Osterhaus AD, van der Eijk AA. Hepatitis E virus infection among solid organ transplant recipients, the Netherlands. Emerg Infect Dis. 2012;18:869-872.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 116]  [Cited by in F6Publishing: 124]  [Article Influence: 11.3]  [Reference Citation Analysis (0)]
162.  Kamar N, Selves J, Mansuy JM, Ouezzani L, Péron JM, Guitard J, Cointault O, Esposito L, Abravanel F, Danjoux M, Durand D, Vinel JP, Izopet J, Rostaing L. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358:811-817.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1005]  [Cited by in F6Publishing: 923]  [Article Influence: 57.7]  [Reference Citation Analysis (0)]
163.  Haagsma EB, van den Berg AP, Porte RJ, Benne CA, Vennema H, Reimerink JH, Koopmans MP. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl. 2008;14:547-553.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 249]  [Cited by in F6Publishing: 250]  [Article Influence: 15.6]  [Reference Citation Analysis (0)]
164.  von Felden J, Alric L, Pischke S, Aitken C, Schlabe S, Spengler U, Giordani MT, Schnitzler P, Bettinger D, Thimme R, Xhaard A, Binder M, Ayuk F, Lohse AW, Cornelissen JJ, de Man RA, Mallet V. The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study. J Hepatol. 2019;71:465-472.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 45]  [Cited by in F6Publishing: 49]  [Article Influence: 9.8]  [Reference Citation Analysis (0)]
165.  Cao D, Cao QM, Subramaniam S, Yugo DM, Heffron CL, Rogers AJ, Kenney SP, Tian D, Matzinger SR, Overend C, Catanzaro N, LeRoith T, Wang H, Piñeyro P, Lindstrom N, Clark-Deener S, Yuan L, Meng XJ. Pig model mimicking chronic hepatitis E virus infection in immunocompromised patients to assess immune correlates during chronicity. Proc Natl Acad Sci U S A. 2017;114:6914-6923.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 56]  [Cited by in F6Publishing: 59]  [Article Influence: 8.4]  [Reference Citation Analysis (0)]
166.  Saravanabalaji S, Tripathy AS, Dhoot RR, Chadha MS, Kakrani AL, Arankalle VA. Viral load, antibody titers and recombinant open reading frame 2 protein-induced TH1/TH2 cytokines and cellular immune responses in self-limiting and fulminant hepatitis e. Intervirology. 2009;52:78-85.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 73]  [Cited by in F6Publishing: 76]  [Article Influence: 5.1]  [Reference Citation Analysis (0)]
167.  Péron JM, Abravanel F, Guillaume M, Gérolami R, Nana J, Anty R, Pariente A, Renou C, Bureau C, Robic MA, Alric L, Vinel JP, Izopet J, Kamar N. Treatment of autochthonous acute hepatitis E with short-term ribavirin: a multicenter retrospective study. Liver Int. 2016;36:328-333.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 47]  [Cited by in F6Publishing: 49]  [Article Influence: 6.1]  [Reference Citation Analysis (0)]
168.  McPherson S, Elsharkawy AM, Ankcorn M, Ijaz S, Powell J, Rowe I, Tedder R, Andrews PA. Summary of the British Transplantation Society UK Guidelines for Hepatitis E and Solid Organ Transplantation. Transplantation. 2018;102:15-20.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 43]  [Cited by in F6Publishing: 43]  [Article Influence: 7.2]  [Reference Citation Analysis (0)]
169.  European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol. 2018;68:1256-1271.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 15]  [Cited by in F6Publishing: 14]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
170.  Wang Y, Zhou X, Debing Y, Chen K, Van Der Laan LJ, Neyts J, Janssen HL, Metselaar HJ, Peppelenbosch MP, Pan Q. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. Gastroenterology. 2014;146:1775-1783.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 133]  [Cited by in F6Publishing: 135]  [Article Influence: 13.5]  [Reference Citation Analysis (0)]
171.  Kamar N, Lhomme S, Abravanel F, Marion O, Peron JM, Alric L, Izopet J. Treatment of HEV Infection in Patients with a Solid-Organ Transplant and Chronic Hepatitis. Viruses. 2016;8.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 28]  [Cited by in F6Publishing: 29]  [Article Influence: 3.6]  [Reference Citation Analysis (0)]
172.  Gorris M, van der Lecq BM, van Erpecum KJ, de Bruijne J. Treatment for chronic hepatitis E virus infection: A systematic review and meta-analysis. J Viral Hepat. 2021;28:454-463.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 15]  [Cited by in F6Publishing: 15]  [Article Influence: 5.0]  [Reference Citation Analysis (0)]
173.  De Winter BCM, Hesselink DA, Kamar N. Dosing ribavirin in hepatitis E-infected solid organ transplant recipients. Pharmacol Res. 2018;130:308-315.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 10]  [Cited by in F6Publishing: 12]  [Article Influence: 2.0]  [Reference Citation Analysis (1)]
174.  Kamar N, Lhomme S, Abravanel F, Cointault O, Esposito L, Cardeau-Desangles I, Del Bello A, Dörr G, Lavayssière L, Nogier MB, Guitard J, Ribes D, Goin AL, Broué P, Metsu D, Sauné K, Rostaing L, Izopet J. An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients. Transplantation. 2015;99:2124-2131.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 55]  [Cited by in F6Publishing: 55]  [Article Influence: 6.9]  [Reference Citation Analysis (0)]
175.  Todt D, Meister TL, Steinmann E. Hepatitis E virus treatment and ribavirin therapy: viral mechanisms of nonresponse. Curr Opin Virol. 2018;32:80-87.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 38]  [Cited by in F6Publishing: 33]  [Article Influence: 5.5]  [Reference Citation Analysis (0)]
176.  Alric L, Bonnet D, Laurent G, Kamar N, Izopet J. Chronic hepatitis E virus infection: successful virologic response to pegylated interferon-alpha therapy. Ann Intern Med. 2010;153:135-136.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 59]  [Cited by in F6Publishing: 61]  [Article Influence: 4.4]  [Reference Citation Analysis (0)]
177.  Kamar N, Abravanel F, Garrouste C, Cardeau-Desangles I, Mansuy JM, Weclawiak H, Izopet J, Rostaing L. Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. Nephrol Dial Transplant. 2010;25:2792-2795.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 86]  [Cited by in F6Publishing: 78]  [Article Influence: 5.6]  [Reference Citation Analysis (0)]
178.  Rivero-Juarez A, Lopez-Lopez P, Frias M, Rivero A. Hepatitis E Infection in HIV-Infected Patients. Front Microbiol. 2019;10:1425.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 20]  [Cited by in F6Publishing: 22]  [Article Influence: 4.4]  [Reference Citation Analysis (0)]
179.  Nakano R, Ohira M, Ishiyama K, Ide K, Kobayashi T, Tahara H, Shimizu S, Arihiro K, Imamura M, Chayama K, Tanaka Y, Ohdan H. Acute Graft Rejection and Formation of De Novo Donor-Specific Antibodies Triggered by Low Cyclosporine Levels and Interferon Therapy for Recurrent Hepatitis C Infection After Liver Transplantation: A Case Report. Transplant Proc. 2017;49:1634-1638.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4]  [Cited by in F6Publishing: 3]  [Article Influence: 0.5]  [Reference Citation Analysis (0)]
180.  Selzner N, Guindi M, Renner EL, Berenguer M. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol. 2011;55:207-217.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 82]  [Cited by in F6Publishing: 86]  [Article Influence: 6.6]  [Reference Citation Analysis (0)]
181.  Kamar N, Rostaing L, Abravanel F, Garrouste C, Esposito L, Cardeau-Desangles I, Mansuy JM, Selves J, Peron JM, Otal P, Muscari F, Izopet J. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis. 2010;50:e30-e33.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 149]  [Cited by in F6Publishing: 141]  [Article Influence: 10.1]  [Reference Citation Analysis (0)]
182.  Haagsma EB, Riezebos-Brilman A, van den Berg AP, Porte RJ, Niesters HG. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. Liver Transpl. 2010;16:474-477.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 32]  [Cited by in F6Publishing: 56]  [Article Influence: 4.0]  [Reference Citation Analysis (0)]
183.  Ollivier-Hourmand I, Lebedel L, Lecouf A, Allaire M, Nguyen TTN, Lier C, Dao T. Pegylated interferon may be considered in chronic viral hepatitis E resistant to ribavirin in kidney transplant recipients. BMC Infect Dis. 2020;20:522.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3]  [Cited by in F6Publishing: 3]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
184.  Dao Thi VL, Debing Y, Wu X, Rice CM, Neyts J, Moradpour D, Gouttenoire J. Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin. Gastroenterology. 2016;150:82-85.e4.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 138]  [Cited by in F6Publishing: 141]  [Article Influence: 17.6]  [Reference Citation Analysis (0)]
185.  van der Valk M, Zaaijer HL, Kater AP, Schinkel J. Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection. J Hepatol. 2017;66:242-243.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 55]  [Cited by in F6Publishing: 56]  [Article Influence: 8.0]  [Reference Citation Analysis (0)]
186.  van Wezel EM, de Bruijne J, Damman K, Bijmolen M, van den Berg AP, Verschuuren EAM, Ruigrok GA, Riezebos-Brilman A, Knoester M. Sofosbuvir Add-on to Ribavirin Treatment for Chronic Hepatitis E Virus Infection in Solid Organ Transplant Recipients Does Not Result in Sustained Virological Response. Open Forum Infect Di. 2019;6.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 15]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
187.  Cornberg M, Pischke S, Müller T, Behrendt P, Piecha F, Benckert J, Todt D, Steinmann E, Papkalla A, von Karpowitz M, Koch A, Lohse A, Hardtke S, Manns MP, Wedemeyer H. Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - The HepNet SofE pilot study. J Hepatol. 2020;73:696-699.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 22]  [Cited by in F6Publishing: 22]  [Article Influence: 5.5]  [Reference Citation Analysis (0)]
188.  Tedder RS, Ijaz S, Kitchen A, Ushiro-Lumb I, Tettmar KI, Hewitt P, Andrews N. Hepatitis E risks: pigs or blood-that is the question. Transfusion. 2017;57:267-272.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 56]  [Cited by in F6Publishing: 57]  [Article Influence: 8.1]  [Reference Citation Analysis (0)]
189.  Denner J. Hepatitis E virus (HEV)-The Future. Viruses. 2019;11.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 43]  [Cited by in F6Publishing: 38]  [Article Influence: 7.6]  [Reference Citation Analysis (0)]
190.  Wu X, Chen P, Lin H, Hao X, Liang Z. Hepatitis E virus: Current epidemiology and vaccine. Hum Vaccin Immunother. 2016;12:2603-2610.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 28]  [Cited by in F6Publishing: 35]  [Article Influence: 4.4]  [Reference Citation Analysis (0)]
191.  Denner J, Pischke S, Steinmann E, Blümel J, Glebe D. Why all blood donations should be tested for hepatitis E virus (HEV). BMC Infect Dis. 2019;19:541.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 24]  [Cited by in F6Publishing: 26]  [Article Influence: 5.2]  [Reference Citation Analysis (0)]
192.  Domanović D, Tedder R, Blümel J, Zaaijer H, Gallian P, Niederhauser C, Sauleda Oliveras S, O'Riordan J, Boland F, Harritshøj L, Nascimento MSJ, Ciccaglione AR, Politis C, Adlhoch C, Flan B, Oualikene-Gonin W, Rautmann G, Strengers P, Hewitt P. Hepatitis E and blood donation safety in selected European countries: a shift to screening? Euro Surveill. 2017;22.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 112]  [Cited by in F6Publishing: 123]  [Article Influence: 17.6]  [Reference Citation Analysis (0)]
193.  Matsubayashi K, Sakata H, Ikeda H. Hepatitis E virus infection and blood transfusion in Japan. ISBT Sci Ser. 2011;6:344-349.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 13]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
194.  Lee CK, Chau TN, Lim W, Tsoi WC, Lai ST, Lin CK. Prevention of transfusion-transmitted hepatitis E by donor-initiated self exclusion. Transfus Med. 2005;15:133-135.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 15]  [Cited by in F6Publishing: 14]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]
195.  Pawlotsky JM. Hepatitis E screening for blood donations: an urgent need? Lancet. 2014;384:1729-1730.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 37]  [Cited by in F6Publishing: 37]  [Article Influence: 3.7]  [Reference Citation Analysis (0)]
196.  Boland F, Martinez A, Pomeroy L, O'Flaherty N. Blood Donor Screening for Hepatitis E Virus in the European Union. Transfus Med Hemother. 2019;46:95-103.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 43]  [Cited by in F6Publishing: 47]  [Article Influence: 9.4]  [Reference Citation Analysis (0)]
197.   American Association of Blood Banks. (2014) Hepatitis E virus [cited 20 March 2021]. Available from: https://www.aabb.org/docs/default-source/default-document-library/regulatory/eid/hepatitis-e-virus.pdf?sfvrsn=9f532d0e_2.  [PubMed]  [DOI]  [Cited in This Article: ]
198.  Kamp C, Blümel J, Baylis SA, Bekeredjian-Ding I, Chudy M, Heiden M, Henseler O, Keller-Stanislawski B, de Vos AS, Funk MB. Impact of hepatitis E virus testing on the safety of blood components in Germany - results of a simulation study. Vox Sang. 2018;113:811-813.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 14]  [Cited by in F6Publishing: 14]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
199.  Bi H, Yang R, Wu C, Xia J. Hepatitis E virus and blood transfusion safety. Epidemiol Infect. 2020;148:e158.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 29]  [Article Influence: 7.3]  [Reference Citation Analysis (0)]
200.  Pischke S, Peron JM, von Wulffen M, von Felden J, Höner Zu Siederdissen C, Fournier S, Lütgehetmann M, Iking-Konert C, Bettinger D, Par G, Thimme R, Cantagrel A, Lohse AW, Wedemeyer H, de Man R, Mallet V. Chronic Hepatitis E in Rheumatology and Internal Medicine Patients: A Retrospective Multicenter European Cohort Study. Viruses. 2019;11.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23]  [Cited by in F6Publishing: 23]  [Article Influence: 4.6]  [Reference Citation Analysis (0)]
201.  Bauer H, Luxembourger C, Gottenberg JE, Fournier S, Abravanel F, Cantagrel A, Chatelus E, Claudepierre P, Hudry C, Izopet J, Fabre S, Lefevre G, Marguerie L, Martin A, Messer L, Molto A, Pallot-Prades B, Pers YM, Roque-Afonso AM, Roux C, Sordet C, Soubrier M, Veissier C, Wendling D, Péron JM, Sibilia J; Club Rhumatismes et Inflammation, a section of the French Society of Rheumatology. Outcome of hepatitis E virus infection in patients with inflammatory arthritides treated with immunosuppressants: a French retrospective multicenter study. Medicine (Baltimore). 2015;94:e675.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 46]  [Cited by in F6Publishing: 38]  [Article Influence: 4.2]  [Reference Citation Analysis (0)]
202.  Kenfak-Foguena A, Schöni-Affolter F, Bürgisser P, Witteck A, Darling KE, Kovari H, Kaiser L, Evison JM, Elzi L, Gurter-De La Fuente V, Jost J, Moradpour D, Abravanel F, Izpopet J, Cavassini M; Data Center of the Swiss HIV Cohort Study, Lausanne, Switzerland. Hepatitis E Virus seroprevalence and chronic infections in patients with HIV, Switzerland. Emerg Infect Dis. 2011;17:1074-1078.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 95]  [Cited by in F6Publishing: 105]  [Article Influence: 8.1]  [Reference Citation Analysis (0)]
203.  Buescher G, Ozga AK, Lorenz E, Pischke S, May J, Addo MM, Horvatits T. Hepatitis E seroprevalence and viremia rate in immunocompromised patients: a systematic review and meta-analysis. Liver Int. 2021;41:449-455.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 9]  [Cited by in F6Publishing: 10]  [Article Influence: 3.3]  [Reference Citation Analysis (0)]
204.  Navaneethan U, Al Mohajer M, Shata MT. Hepatitis E and pregnancy: understanding the pathogenesis. Liver Int. 2008;28:1190-1199.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 284]  [Cited by in F6Publishing: 262]  [Article Influence: 16.4]  [Reference Citation Analysis (0)]
205.  Anty R, Ollier L, Péron JM, Nicand E, Cannavo I, Bongain A, Giordanengo V, Tran A. First case report of an acute genotype 3 hepatitis E infected pregnant woman living in South-Eastern France. J Clin Virol. 2012;54:76-78.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 63]  [Cited by in F6Publishing: 67]  [Article Influence: 5.6]  [Reference Citation Analysis (0)]
206.  Tabatabai J, Wenzel JJ, Soboletzki M, Flux C, Navid MH, Schnitzler P. First case report of an acute hepatitis E subgenotype 3c infection during pregnancy in Germany. J Clin Virol. 2014;61:170-172.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 43]  [Cited by in F6Publishing: 47]  [Article Influence: 4.7]  [Reference Citation Analysis (0)]
207.  Bouthry E, Benachi A, Vivanti AJ, Letamendia E, Vauloup-Fellous C, Roque-Afonso AM. Autochthonous Hepatitis E during Pregnancy, France. Emerg Infect Dis. 2018;24:1586-1587.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11]  [Cited by in F6Publishing: 11]  [Article Influence: 2.2]  [Reference Citation Analysis (0)]
208.  Jilani N, Das BC, Husain SA, Baweja UK, Chattopadhya D, Gupta RK, Sardana S, Kar P. Hepatitis E virus infection and fulminant hepatic failure during pregnancy. J Gastroenterol Hepatol. 2007;22:676-682.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 159]  [Cited by in F6Publishing: 153]  [Article Influence: 9.0]  [Reference Citation Analysis (0)]
209.  Kar P, Jilani N, Husain SA, Pasha ST, Anand R, Rai A, Das BC. Does hepatitis E viral load and genotypes influence the final outcome of acute liver failure during pregnancy? Am J Gastroenterol. 2008;103:2495-2501.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 99]  [Cited by in F6Publishing: 95]  [Article Influence: 5.9]  [Reference Citation Analysis (0)]
210.  Kar P, Sengupta A. A guide to the management of hepatitis E infection during pregnancy. Expert Rev Gastroenterol Hepatol. 2019;13:205-211.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 16]  [Cited by in F6Publishing: 17]  [Article Influence: 3.4]  [Reference Citation Analysis (0)]
211.  Horvatits T, Westhölter D, Peine S, Schulze Zur Wiesch J, Lohse AW, Lütgehetmann M, Pischke S. Lack of evidence for human serum albumin as major source of HEV infections. Transfus Med. 2018;28:470-471.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2]  [Cited by in F6Publishing: 2]  [Article Influence: 0.3]  [Reference Citation Analysis (0)]
212.  Juhl D, Nowak-Göttl U, Blümel J, Görg S, Hennig H. Lack of evidence for the transmission of hepatitis E virus by coagulation factor concentrates based on seroprevalence data. Transfus Med. 2018;28:427-432.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3]  [Cited by in F6Publishing: 3]  [Article Influence: 0.4]  [Reference Citation Analysis (0)]
213.  de Vos AS, Janssen MP, Zaaijer HL, Hogema BM. Cost-effectiveness of the screening of blood donations for hepatitis E virus in the Netherlands. Transfusion. 2017;57:258-266.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 34]  [Cited by in F6Publishing: 37]  [Article Influence: 5.3]  [Reference Citation Analysis (0)]
214.  Gallian P, Lhomme S, Morel P, Gross S, Mantovani C, Hauser L, Tinard X, Pouchol E, Djoudi R, Assal A, Abravanel F, Izopet J, Tiberghien P. Risk for Hepatitis E Virus Transmission by Solvent/Detergent-Treated Plasma. Emerg Infect Dis. 2020;26:2881-2886.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5]  [Cited by in F6Publishing: 6]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
215.  Hauser L, Roque-Afonso AM, Beylouné A, Simonet M, Deau Fischer B, Burin des Roziers N, Mallet V, Tiberghien P, Bierling P. Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. Blood. 2014;123:796-797.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 100]  [Cited by in F6Publishing: 110]  [Article Influence: 11.0]  [Reference Citation Analysis (0)]
216.  Farcet MR, Lackner C, Antoine G, Rabel PO, Wieser A, Flicker A, Unger U, Modrof J, Kreil TR. Hepatitis E virus and the safety of plasma products: investigations into the reduction capacity of manufacturing processes. Transfusion. 2016;56:383-391.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 29]  [Cited by in F6Publishing: 29]  [Article Influence: 3.2]  [Reference Citation Analysis (0)]
217.  Kapsch AM, Farcet MR, Wieser A, Ahmad MQ, Miyabayashi T, Baylis SA, Blümel J, Kreil TR. Antibody-enhanced hepatitis E virus nanofiltration during the manufacture of human immunoglobulin. Transfusion. 2020;60:2500-2507.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4]  [Cited by in F6Publishing: 5]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
218.  Praditya D, Friesland M, Gravemann U, Handke W, Todt D, Behrendt P, Müller TH, Steinmann E, Seltsam A. Hepatitis E virus is effectively inactivated in platelet concentrates by ultraviolet C light. Vox Sang. 2020;115:555-561.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4]  [Cited by in F6Publishing: 4]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]